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Glutathione, a ubiquitous intracellular tripeptide, protects cells by reacting with
electrophiles and radicals that can damage cellular macromolecules. However,
glutathione conjugation is now recognized as one mechanism by which drugs and
xenobiotics can also be converted to reactive intermediates having toxic consequences
to cells. The halogenated alkane 1,2-dichloroethane forms S-(2-chloroethyl)
glutathione (CEG) upon glutathione conjugation which can cyclize to an episulfonium
ion. The episulfonium ion of CEG is a potent electrophile that can alkylate the N7
position of guanine in DNA. To investigate the possible role of protein alkylation by
CEG as a determinant in the toxicity of 1,2-dichloroethane, it is necessary to better
understand the alkylation chemistry of CEG toward proteins. Although covalent
binding has been known to be correlated with the toxicity of many chemicals, it is
now thought covalent binding is selective towards specific protein targets. My work
has attempted to determine if the alkylation event is also selective for certain amino
acids in a protein. To answer the specific question of where the adducts derived from
the episulfonium ion of CEG have formed, a combination of mass spectrometric
techniques, including tandem mass spectrometry, were employed. As models, I
employed one peptide, oxytocin, and two proteins, human hemoglobin and E. coli
thioredoxin. The results of my work show that for the episulfonium ion of CEG,
alkylation is highly selective for cysteine over other amino acids with tyrosine being
the next most reactive amino acid residue. However, the episulfonium ion is also
selective amongst protein thiols as certain cysteine residues are not alkylated, possibly
due to steric hindrance and/or charge effects.
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Chapter I
Introduction
The compound known as glutathione (GSH), first characterized chemically in
1929 by F. G. Hopkins, is present in animal cells and also in many plants and
bacteria.It has been the subject of extensive investigation due to its importance in
biology. Glutathione is a tripeptide composed of y-glutamyl-L-cysteinylglycine; the
cysteine thiol group has a pKa of approximately 8.6 which is important for many of its
functions (Reed, 1985). The bond between cysteine and glutamic acid is not a normal
peptide bond, but has a y-glutamyl link formed through the y-carboxylate of glutamate
with the a-amino group of cysteine (Figure 1.1); this serves to make it resistant to
degradative peptidases. The cellular concentrations of reduced GSH are normally
millimolar, ranging from 0.5 mM to 10 inM. It is now known that there are two
distinct pools of GSH present in hepatocytes (Edwards and Westerfield, 1952; Riley
and Lehninger, 1964). The cytosolic pool is the largest with approximately 85-90% of
GSH; the remaining GSH is present in the mitochondria (Reed, 1985).
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Figure 1.1Structure of glutathione showing the component amino acids.2
Synthesis of GSH takes place intracellularly and requires ATP and the
sequential activity of two enzymes: y-glutamylcysteine synthetase (y-GCS) (EC
6.3.22) and GSH synthetase (EC 6.3.2.3) (Figure 1.2). Regulation of GSH synthesis
can occur by feedback inhibition in which GSH controls y-GCS activity.Recent
work suggests that oxidative stress induced by quinones may increase GSH levels by a
mechanism that elevates y-GCS mRNA expression (Shi, et al., 1994). Inhibition of
GSH synthesis has been studied due to its potential application in cancer medicine,
whereby depleting cancer cells of GSH is hypothesized to sensitize them to
chemotherapy or radiation. GSH synthesis can be decreased by buthionine sulfoximine
(BSO), which inhibits y-glutamylcysteine synthetase. However, when treating normal
and transformed human lung fibroblast cells with BSO, normal cells were found more
sensitive to the cytotoxic effects of BSO (Wan and St. Clair, 1993).
Cysteine Glycine
ATP ADP + Pi ATP ADP +
y-Glu-Cys y-Glu-Cys-Gly
GSH Synthetase
Glutamate
1-Glutamylcysteine-
synthetase
Figure 1.2 Biosynthesis of GSH.
GSH is an important part of the cell's defense mechanism towards xenobiotics
because of its ability to detoxify reactive chemicals (Reed, 1985). The soft
nucleophilic thiol is able to react non-enzymatically with soft electrophiles, such as, N-
acetyl-p-benzoquinoneimine (NAPBQI) or 4-hydroxynonenal. Reactive hard
electrophiles, such as, benzo[a]pyrene-7,8-dio1-9,10-epoxide, require enzymatic
conjugation by glutathione S-transferase (GST) (Ketterer, 1986). GSH conjugation,
either enzymatic or non-enzymatic, serves two purposes:1) eliminating the ability of
a reactive electrophile to combine with critical cellular macromolecules
by forming a chemically stable thioether, and, 2) creating a species with greater
hydrophilic character that is more readily excreted from the body.3
The GST enzymes catalyze GSH conjugation with drugs and chemicals having
diverse structures and are therefore considered the most important enzymes for
detoxification of electrophilic compounds (Armstrong, 1991). They were originally
classified according to their isoelectric properties and substrate specificities, but this
has been replaced in recent years in favor of a classification system based on genetics.
The mammalian cytosolic enzymes are organized into four classes: a, g, it and 9.
Species differences do exist, however, with respect to the expression of certain
enzymes in the liver. For example, enzymatic GSH conjugation is involved in
detoxification of the putative carcinogenic metabolite of aflatoxin, AFB-8,9-exo-
epoxide. Mice express high levels of the a-class GST isozyme responsible for this
reaction which makes mice resistant to the carcinogenic effects of aflatoxin. In
contrast, the constitutively expressed enzymes in humans have little activity towards
reactive metabolites of aflatoxin Bl, which suggests that humans should be quite
sensitive to the genotoxic effects of aflatoxin (Eaton and Gallagher, 1994). In humans,
enzyme polymorphisms exist and may increase or decrease a person's susceptibility to
a chemical. Differential susceptibility is illustrated by the finding that a GST,
belonging to the 9 -class found in erythrocytes, capable of conjugating a number of
halogenated methanes to the S-methylglutathione conjugate, is present only in
approximately 60% of humans tested (Hallier, et al., 1993; Pemble, et al., 1994).
Many GSH-conjugates formed in the liver are metabolized to mercapturates by
the sequential action of several enzymes, followed by excretion in the urine; this is the
mercapturic acid biosynthetic pathway (Figure 1.3). The enzymes y-glutamyl
transferase (y-GT) and cysteinylglycine dipeptidase are membrane bound enzymes that
catalyze the extracellular cleavage of glutamyl and glycyl residues respectively, from
the GSH-conjugate. N-acetyltransferase is a microsomal enzyme, found in both
kidney and liver, that acetylates the amine functionality of the cysteine conjugate and
requires the acetyl donor acetyl CoA. y-GT and dipeptidases are found in highest
concentration in the kidney and it was assumed for some time that mercapturic acid
biosynthesis was exclusively an interorgan process whereby the GSH-conjugate
synthesized in the liver was transported to the kidney for catabolism. Recent evidence4
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Figure 1.3 Mercapturic acid biosynthesis showing transformation of naphthalene.5
indicates that xenobiotics may be converted to mercapturates exclusively in the liver
via the intrahepatic y-glutarnyl cycle (Hinchman and Ballatori, 1994). In this process,
GSH-conjugates formed in the liver are transported across the cannicular membrane
into the bile where they are broken down to cysteine conjugates. After reabsorption
by the liver, the cysteine-conjugates are N-acetylated and reexcreted. Critical to either
pathway is the transport of the GSH-conjugate out of the hepatocyte. Ishikawa has
characterized an ATP-dependent GSH-conjugate export pump (Ishikawa, 1992).
Removal of GSH-conjugates is important because their accumulation can decrease the
efficiency of GST enzymes and thereby decrease detoxification reactions. For
example, several GSH-conjugates of halogenated quinones have been shown to
irreversibly inactivate GST (van Ommen, et al., 1991).
GSH is also important as a defense against reactive oxygen species generated
as a consequence of aerobic metabolism (Cotgreave, et al., 1988). Reactive oxygen
species include hydrogen peroxide (H202), superoxide anion radical, hydroxyl radical
and singlet oxygen. GSH can serve as an intracellular reductant by functioning as a
cosubstrate for selenium dependent GSH-permddase; this enzyme can convert H202 to
H2O with the simultaneous production of glutathione disulfide (GSSG). GSH readily
donates a hydrogen atom to most carbon- and oxygen- radical species to yield the thiyl
radical of GSH, two of which combine to form GSSG. Glutathione reductase has the
primary role of catalyzing the reduction of GSSG to GSH in a reduced pyridine
nucleotide (NADPH) mediated reaction; in conjunction with GSH peroxidase, this
constitutes the GSH redox cycle (Figure 1.4).
Currently, much data has accumulated on the effects of GSH and its relation to
the formation of senile cataracts. Cataracts is a condition of opacity in the lens and is
commonly associated with the aging process and oxidative stress. When suckling mice
were exposed to BSO, decreased GSH levels and electrolyte changes were observe
preceding cataract formation (Calvin, et al., 1992). In humans, one study showed a
inverse relationship between the amount of y-glutamylcysteine synthetase activity and
degree of subcapsular cataract (Rathbun, et al., 1993). Finally, administration of GSH
isopropyl ester (YM737) to rats significantly delayed the x-ray induced development6
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Figure 1.4 Glutathione redox cycle
of cataracts (Kobayashi, et al., 1993). Taken together, experimental evidence supports
the hypothesis that chronic damage by oxidative stress produces cataracts and that
GSH can have a beneficial role in preventing them.
Several endogenous compounds are converted to pharmacologically active
compounds following GSH or cysteine conjugation. The best characterized to date are
the leukotrienes, compounds which comprise the slow-reacting substance of
anaphylaxis (Slauson and Cooper, 1990) and are potent smooth muscle spasmogens.
Leukotriene C4 (LTC4) arises from GSH conjugation with the epoxide function of
LTA4 catalyzed by LTC4 sythase. As a consequence of glutathione synthetase
deficiency in afflicted individuals, LTC4 is significantly reduced in monocytes and
neutrophils which might be involved in the pathophysiology of glutathione synthetase
deficiency disease (Mayatepek, et al., 1993). There has been a great deal of work
focusing on the nitric oxide molecule and its numerous physiologic functions
(Koshland, 1992). Recent work has suggested a role for GSH in mediating the
bioactivity of NO through the formation of a GSH adduct of NO. Evidence suggests
that this S-nitrosothiol might be the compound with biologic activity.It has been
reported that S-nitrosothiols (RS-NO), in particular the GSH adduct, are present to
varying degrees in different pathologic states in humans and are powerful relaxants of
bronchiole muscle (Gaston, et al., 1993). In addition, i.v. administration of S-
nitrosoglutathione reduced the blood pressure in dogs and monkeys to the same degree7
and with the same rate as sodium nitroprusside (Park, et al., 1993), a drug used in the
treatment of hypertension. More work remains to be performed before definite
conclusions can be made regarding the connection between GSH and nitric oxide.
Nevertheless, these examples suggest the possibility that other GSH conjugates yet to
be discovered may have important pharmacologic functions.
Although GSH functions to protect cells from reactive intermediates, it has
become increasingly clear that GSH can also enhance the toxicity of many chemicals
(Monks and Lau, 1994). These are termed toxification reactions to distinguish them
from detoxification reactions. An enzyme often associated with toxification reactions
is cysteine conjugate 13-lyase ([3- lyase) which acts on cysteine conjugates formed by
the mercapturic acid pathway. 13-lyase contains pyridoxal phosphate and is present in
the renal proximal tubule.It splits the bond between cysteine and the conjugate
releasing a reactive species that can covalently bind to tissue macromolecules. Several
aliphatic halogenated alkenes are potent nephrotoxicants as a result of the activity of
3 -lyase (Commandeur and Vermeulen, 1990).As an example, hexachloro-1,3-
butadiene (HCBD) is nephrocarcinogenic when chronically administered to rats and
mutagenic in bacteria The mutagenicity was reduced in the presence of the
aminooxyacetic acid, a f3 -lyase inhibitor used to differentiate pathways dependent on
13-lyase, implying that this enzyme is required for activation of HCBD. Conjugation of
certain quinones with GSH also results in the formation of selective nephrotoxicants.
Bromobenzene is metabolized to 2-bromo-(di-glutathion-S-yl)hydroquinone and other
isomers which may react with cellular macromolecules directly or generate reactive
oxygen species (Monks and Lau, 1994).
An alternative mechanism of GSH-conjugate mediated toxicity occurs when the
initial conjugation reaction is reversible (Baillie and Kassahun, 1994). Spontaneous
reversibility of the GSH-conjugate bond appears to be limited to certain chemical
classes, including isothiocyanates, isocyanates, a,f3- unsaturated carbonyl compounds,
formamides, alkyl carbamates and ureas (Baillie and Slatter, 1991). The significance of
reversibility is that certain chemically reactive compounds can be transported as the
GSH conjugate to distant target organs where the chemical is released to exert toxic8
effects.Methylisocyanate (MIC), the chemical released during the Bhopal disaster,
causes toxicity both to pulmonary and extra-pulmonary target organs (Lepkowski,
1994). Toxicity is thought due to carbamylation of critical macromolecules
following release of MIC from GSH; this demonstrates the ability of GSH tocarry
MIC from the lungs to the kidney.
The vicinal dihaloalkanes undergo a unique activation mechanism upon GSH
conjugation. The first step in activation by GSH conjugation is the enzymatic
displacement of a halogen ion by the thiol group of GSH catalyzed by GST.The
conjugation product, S-(2-haloethyl)GSH, is known as a sulfur half-mustard.
Rearrangement of the sulfur mustard can occur by intramolecular displacement of the
remaining halogen (13-elimination) by sulfur (Figure 1.5). The resulting episulfonium
ion, also known as a thiiranium ion, is an electrophile capable of reacting with
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Figure 1.5 Mechanism of formation of the episulfonium ion of CEG.9
nucleophilic sites on tissue macromolecules such as DNA and proteins (Dohn and
Casida, 1987; Smit, et al., 1978). Although the half-life of S-(2-bromoethyl)
glutathione is less than 10 seconds, it is stable enough to diffuse from hepatocytes
where it is formed and adduct endogenously added DNA (Guengerich and
Ozawa, 1983). The major adduct has been identified as S-[2-(N7-guany1)-
ethyl]glutathione. The formation of the episulfonium ion is highly dependant on
suitable stereochemistry; this is demonstrated by the lack of mutagenicity of 1,3 and
1,4-dibromobutane, presumably, because increased chain length hinders intramolecular
displacement of bromine by sulfur. The leaving group ability of the halogen
substituent also is a determinant in mutagenicity. The higher mutagenicity of 1,2-
dibromoethane (DBE) compared to 1,2-dichloroethane (DCE) is explained on the basis
of better leaving ability of bromine as compared to chlorine when forming their
respective episulfonium ions (van Bladeren, et al., 1981a). The agricultural chemical
1,2-dibromo-2-chloropropane (DBCP) can be conjugated with GSH to form an acutely
toxic conjugate that causes renal necrosis and testicular atrophy (Kluwe, 1981); the
conjugate is not, however, mutagenic in bacterial assays (Monks and Lau, 1994). The
formation of two possible episulfonium ions allows for several different adducts to be
formed with DNA as was found to be the case by Humphreys and coworkers.
Reaction of synthetically prepared conjugate with calf thymus DNA resulted in the
formation of three major N7-guanyl adducts, and one 06, N7-dialkylated adduct
(Humphreys, et al., 1991). A bis-guanyl adduct was also identified illustrating the
possibility that DBCP might serve as a cross-linking agent which might explain the
toxic effect of DBCP in vivo.
S-thiolation is the general term denoting the reversible oxidation of protein
thiols by disulfides and describes the combination of low molecular weight thiols with
protein sulfhydryls (Ziegler, 1985). When reaction is with GSH, cysteine or
cysteamine, for example, the process is known as S-glutathiolation, S-cystelation or S-
cystamylation, respectively (Thomas, et al., 1994).It is known that increased
oxidation of GSH to GSSG can lead to protein S-thiolation in vivo by protein/disulfide
exchange (Reed, 1990).It is also possible that a radical initiated process may lead to10
S-thiolation as well. Many proteins are known to undergo S-thiolation (Thomas, Chai
and Jung, 1994) but the consequences of S-thiolation are known for onlya few
proteins. Evidence exists that support the hypothesis that protein S-thiolation isone
mechanism by which the activity of certain enzymes may be modulated by changes in
the cellular thiol/disulfide redox potential (Ziegler, 1985). For example, the activity of
the glycolytic enzyme phosphofructokinase has been shown to be regulated bya
reversible thiol/disulfide exchange with micromolar concentrations of GSSG and other
biologically occurring thiols (Gilbert, 1982). The reverse reaction whereby the
protein thiol is regenerated by a reduced thiol is known as dethiolation and can be
catalyzed by certain redox active enzymes, such as, thioredoxin (Park and Thomas,
1989).
Chemicals that generate reactive oxygen species may result in extensive 5-
thiolation of cellular proteins and may be a common response to oxidative stress
(Chai, et al., 1994). Protein thiol depletion is considered as a possible mechanism of
toxic cell death as it has been observed that loss of protein thiols often proceeds loss
of cell integrity (Snyder, 1990). In hepatocytes treated with diqunt, t-butyl
hydroperoxide or menadione, the sulfhydryl enzyme carbonic anhydrase DI (CA Ill)
formed three different S-thiolated species as determined by isoelectric focusing. The
biological significance, however, of CA DI S-thiolation is unclear as alkylation of the
two reactive sulfhydryls at cys-183 and cys-188 had no effect on enzymatic activity.
It has been suggested that S-thiolation of CA DI may serve to protect other more
critical enzymes during oxidative stress conditions and prevent the formation of
irreversibly oxidized enzymes (Chai, Hendrich and Thomas, 1994).It is also
conceivable that CA HI can trap reactive electrophilic chemicals and thereby protect
critical thiol groups.
Protein disulfides formed as a result of oxidative stress can inactivate vicinal
dithiol containing enzymes and cannot be reduced by physiologic concentrations of
GSH (Gitler, et al., 1994). The explanation for the inability of GSH to reduce protein
disulfides is that GSH initially forms a mixed disulfide with the enzyme (protein-
(SH)-SSG). The partially reduced protein has a thiol in close proximity to the mixed11
disulfide resulting in a high effective thiol concentration. Thus, the most likely
reaction is not with GSH but with the nearby protein sulfhydryl resulting in the
reformation of protein disulfide. Protein disulfide reductases can fulfil the important
function of restoring protein thiols. The reductive functions of thioredoxin are due to
the low plc of the active site thiol on cys-32, which makes this thiol extremely
reactive; the low pKa of the active site thiol is thought due to interaction with basic
residues around the active site ( Holmgren, 1985). Thioredoxin is a component of the
thioredoxin system which along with thioredoxin reductase and NADPH, can reduce
oxidized proteins (Holmgren, 1989) some ten thousand times more effectively than
DTT (Gitler, Mogyoros and Kalef, 1994). A "ping-pong" mechanism is thought to be
involved in the reductive process, as illustrated in Figure 1.6.It has also been
reported that thioredoxin can completely regenerate glyceraldehyde 3-phosphate
dehydrogenase (G3PDH) that has been oxidized by hydrogen peroxide. Oxidation of
G3PDH is thought to result in a sulphenic acid rather than disulfide formation so that
it appears that thioredoxin can also reduce monothiol oxidized proteins containing the
cysteine sulfhydryl as sulphenic acid (Fernando, et al., 1992).In contrast,
glutaredoxin, also known as thioltransferase, is more efficient than thioredoxin at
reducing enzymes containing mixed disulfides than enzymes inactivated by mono thiol
oxidation to sulfenic or sulfinic acid (Yoshitake, et al., 1994).
Cyst SH
--->
CYS3S
Figure 1.6 Possible mechanism of thioredoxin catalyzed reduction of protein
disulfides. Adapted from Holmgren.12
Chapter I I
Background
Covalent Binding
Xenobiotics can interact with proteins in a number of ways. Drug binding toa
specific receptor which elicits a particular cellular response is a basic tenet of
pharmacology. In general, drugs bind reversibly so that the drug action is transient.
In the field of toxicology, an important area of study is the action of enzymeson
xenobiotic substrates to transform them chemically. In contrast, many xenobiotic
chemicals can, either directly or following metabolic activation, irreversibly bind to
macromolecules and cause toxicity. Metabolic transformations can be classified into
Phase I and Phase II metabolism. Phase I metabolism, by the P450s and flavin
monooxygenases, generally utilizes molecular oxygen to oxidize the xenobiotic thereby
introducing functional groups such as, hydroxyl or carbonyl functionalities. Phase II
metabolism achieves the formation of a more water soluble compound by
glucuronidation or sulfation of the product produced by Phase I metabolism. Many
chemicals, however, are converted to electrophilic metabolites, electron deficient
species that react readily with electron rich centers. Reaction of electrophilic
metabolites with nucleophilic sites in macromolecules is central to many different
types of toxicity including carcinogenesis, mutagenesis, cellular necrosis,
hypersensitivity reactions, methemoglobinemia, hemolytic anemia, blood dyarasias
and fetotoxicities (Gillette, et al., 1974). Although much information exists regarding
the reactions that produce toxic metabolites and the chemical disposition of these
metabolites, less is known about how they target cellular constituents and how these
interactions cause cell injury (Nelson and Pearson, 1990).
Historically, the concept of electrophilic metabolites was developed by
Elizabeth and James Miller in their studies to elucidate the mechanism of chemical13
carcinogenesis (Miller and IVE ller, 1966). Although they initially studied binding of a
metabolite of the chemical dye, N,N- dimethyl- 4- aminoazobenzene, to hepatic protein
which was found to precede induction of tumors (IVfiller and Miller, 1947), attention
turned to DNA after discovery of its helical duplex structure in 1953. (Watson and
Crick, 1953).Interaction of electrophiles with DNA is a common property of
carcinogens (Miller and Nfiller, 1969). A chemical is called a "procarcinogen" prior
to metabolism and is converted to a "proximate" and finally, to an "ultimate"
carcinogen which is electrophilic (Miller and INkller, 1981). Metabolism to
electrophiles is the common property that explains how structurally diverse chemicals,
such as the classic chemical carcinogens, 2-acetylaminofluorene, 4-aminobiphenyl and
2-napthylamine, can react with DNA. Exceptions are the direct acting alkylating
agents that form electrophiles without metabolic activation, such as, the nitrogen
mustard mechlorethamine. The structural characteristics of many DNA-reactive
metabolite adducts have been determined; this information has allowed progress to be
made in answering the question of how alteration in structure initiates carcinogenesis.
In contrast to DNA and carcinogenesis, much less is known regarding the role that
protein covalent modification plays in producing acute lethal cell injury. Reactive
drug metabolites and protein covalent binding has been extensively studied with
respect to a role in causing the toxicity of certain drugs (Hinson and Roberts, 1992;
Nelson and Pearson, 1990). This line of research was initiated in the late 1960's and
early 1970s' by Brodie, Gillette and coworkers at the National Institutes of Health
(Gillette, Mitchell and Brodie, 1974). Protein binding of carcinogens has also been
investigated extensively. The focus of these studies either investigates basic
mechanisms of carcinogen interactions or, to develop methods of biomonitoring
exposure to carcinogens in the work place (Ehrenberg, et al., 1974).
It is believed that there are two general mechanisms by which protein binding
can lead to toxicity:1) inactivation of a critical regulatory protein(s) or enzymes;
and, 2) formation of a neoantigen that can induce an immune hypersensitivity reaction.
One extensively studied drug illustrating the first possibility is the analgesic
acetaminophen.P450 metabolism of acetaminophen forms a toxic metabolite, N-14
acetyl-p-benzoquinoneimine (NAPBQI). Once formed, NAPBQI may be detoxified by
GSH conjugation, sulfation or glucuronidation (Figure 1.7). However, when these
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Figure 1.7. The reactive metabolite of acetaminophen, NAPBQI, can be detoxified by
sulfation, glucuronidation or GSH conjugation. When these protective pathways are
exhausted, NAPBQI reacts with cellular macromolecules resulting in toxicity.15
detoxification pathways are overwhelmed, centrilobular hepatic necrosis occurs and is
seen in both experimental animals and humans; necrosis is correlated with hepatic
protein binding (Hinson and Roberts, 1992). On a molecular level, NAPBQI reacts
with cysteine to form the 3-(cystein-S-yl)acetaminophen-protein adduct as determined
by mass spectrometry (Hoffmann, et al., 1985). A 44 kDa protein primarily localized
in the microsomal fraction has been identified as the earliest protein to undergo
modification (Birge, et al., 1991). A 56 kDa selenium binding protein has also been
identified as a target of acetaminophen binding (Pumford, et al., 1992). Although
these targets have been identified, it is not known if an essential cellular activity has
been affected accounting for the observed toxicity because the functions of these
proteins are not known.
Idiosyncratic toxicities to xenobiotics are difficult to predict and usually do not
develop immediately, but rather have a latent period. Adverse idiosyncratic reactions
to xenobiotics are characterized by dose independence, are difficult to reproduce in
animals and do not occur in all humans (Pohl, et al., 1988). Some idiosyncratic
reactions might have a congenital basis, such as, glucose-6-phosphate dehydrogenase
deficiency leading to hemolytic anemia; others are known to have an immunologic
basis. Reactive metabolites can combine with protein to form adducts which initially
result in the development of antibodies against the altered protein (Hinson, et al.,
1994; Pohl, 1993). Subsequent exposure to the chemical produces a toxicity as a
result of a hypersensitivity immune response. To date, the most studied drug
producing this type of effect has been halothane. Halothane, a halogenated alkane
with molecular formula 2,2-dichloro-1,1,1-trifluoroethane, produces "halothane
hepatitis" in the liver in a certain fraction of people (1 in 10-20,000) administered this
anesthetic (Pohl, Satoh and Christ, 1988). Halothane can be metabolized by P450 2
El either in a reductive or oxidative process.It is believed that the oxidative pathway,
however, is more important to toxicity due to the formation of a reactive
trifluoroacetyl halide metabolite (Gandolfi, et al., 1980). After formation, the
metabolite is capable of acylating lysine amino acids giving trifluoroacetyl-lysine-
protein adducts. Several major protein targets of known function have been identified16
using antibodies that recognize trifluoroacetylated proteins which include protein
disulfide isomerase (Martin, et al., 1989) and the calcium binding protein, calreticulin
(Butler, et al., 1992). The mechanism of cell death is thought due to cytotoxic cell
killing by lymphocytes that recognize hepatocytes containing trifluoroacetylated
proteins (Vergani, et al., 1980).
Dichloroethane
The 1,2-dihaloalkanes (DHAs) are important industrial chemicals produced on a
worldwide basis. The most important of these is DCE which is also known as
dichloroethylene and ethylene dichloride; the chemical formula is C2H4C12. Physical
and chemical properties of DCE are presented in Table 1.1. DCE is a clear liquid that
evaporates readily at room temperature and has a pleasant smell and a sweet taste
(Williams and Diwan, 1994). In the United States DCE is among the largest-volume
synthetic organic chemicals manufactured with 1990 production approximately 18.6
billion pounds (Kirschner, 1995). The major use for DCE is as feedstock in the
production of vinyl chloride84%) and to a lesser extent, perchlorethylene,
trichloroethylene and 1,1,1-trichloroethane. Additional uses include the manufacture of
paint thinners, acrylic adhesives, rubber cement, leather and metal cleaners, and rubber
goods (Markowitz, 1994). Occupations with the largest numbers of workers exposed
to DCE include automobile mechanics, registered nurses, heavy equipment mechanics,
janitors and machinists (Williams and Diwan, 1994). The general population may be
exposed to DCE in contaminated air, or by drinking contaminated water. Ingestion of
residual DCE on food items is also a possibility. The production of the chemically
related DBE has declined in recent years due to its ban as a fungicide and decrease in
the use of leaded gasoline to which it is added as a lead scavenger.
Acute toxicological properties of DCE following inhalation exposure involve
the central nervous system (CNS) and include symptoms of headache, dizziness,
weakness, cyanosis, muscular spasms, hypotonia, vomiting and unconsciousness17
(Organization, 1987). Cyanosis is a result of either respiratory depressionor
obstruction of the airways due to inflammation of the airways. Oral ingestion of DCE
produces similar, but more pronounced CNS symptoms. It has been reported that
ingestion of 20-50 mL of DCE is lethal in humans (IRPTC, 1984).
DCE is hepatotoxic in humans after acute oral poisoning. A reported dose of ?_
570 mg/kg/day resulted in severe hepatocellular damage and liver atrophy (Williams
and Diwan, 1994).Recently it has been reported that lipoglycoprotein metabolism in
rat hepatocytes may be impaired by DCE (Cottalasso et al., 1994). The block in
secretion of lipoglycoproteins from the Golgi and endoplasmic reticulumoccurs as
early as five minutes after administration of DCE and may be responsible forsome of
the observed hepatotoxic effects such as fatty liver. Renal effects have been observed
Table 1.1 Physical and Chemical Properties of 1,2-Dichloroethane
Property
Molecular weight
Color
Physical state
Melting point
Boiling point
Density (20°C)
Odor
Odor threshold:
Water
Air
Solubility:
Water (20°C)
organic solvents
Partition Coefficients:
Log Ko,
Log Koc
Vapor pressure (20°C)
Henry's Law constant (25°C)
Autoignition temperature
Flashpoint
Information
98.96 gimole
colorless
heavy liquid
-35°C
84°C
1.25 g/mL
Pleasant
20 mg/mL
10-50 ppm
0.87 g/100 ml
Miscible with chlorinated solvents
alcohol, chloroform, ether.
1.47
1.21
61 mm Hg
1.10 x 10 ' atm-m3/mol
413°C
13°C (closed cup)18
in humans following the acute ingestion of DCE. Ingestion of 714mg/kg/day caused
renal damage in the form of bleeding and hyperemia of the kidney (Schonborn,et al.,
1970). Minimal to moderate renal regeneration was also noted in male mice ata dose
of 2,710 mg/kg/day. Bacterial mutagenicity assays have shown that DHAsare
mutagenic in vitro (Cmarick, et al., 1992; Inskeep, et al., 1986; Koga, et al., 1986).
Recently, Ballering and coworkers used the vermillion locus of Drosphila
melanogaster to investigate the DNA sequence changes due to DCE, DBE and 1-
bromo-2-chloroethane (BCE). Their data strongly support the conclusions that DHAs
are genotoxic through modification at ring nitrogensN7 of guanine and N' of
adenineand that the mutagenic action seems to be the formation of non-coding lesions
and/or misrepair (Ballering, et al., 1994). Based upon the available mutagenicity
studies, the International Agency for Research on Cancer (WHO) classifies DCEas a
class 2B carcinogen (possible human carcinogen) while the EPA classifies itas class
B2 (probable human carcinogen). To date, there is no specific evidence relating DCE
exposure with the occurrence of cancer in humans.
For some of the toxic and carcinogenic effects of DCE to be expressed, it must
be metabolized (Figure 1.8). Both microsomal and cytosolic fractionsare capable of
metabolic activation resulting in different reactive metabolites so that two pathways of
DCE metabolism have been proposed:1) P450 oxidation and 2) glutathione
transferase activity with glutathione conjugation (Guengerich, et al., 1980b; Shi and
Hill, 1981). The relative role of these two pathways in the toxicity of DCE has not
yet been unequivocally determined. The microsomal pathway is dependent primarily
on P450 2E1 which can convert DCE into chloroacetaldehyde (Guengerich, et al.,
1980a). This is an alkylating agent that is highly reactive and has been shown capable
of binding to protein (Guengerich, et al., 1981). As P450 2E1 is an ethanol inducible
cytochrome P450, it is expected that ethanol cotreatment would havea profound effect
on metabolism. Low tissue ethanol concentrations were found to stimulate P450
activity towards DCE, while high tissue levels suppress metabolism of DCE (Sato, et
al., 1981). Concurrent administration of disulfiram, a compound that inhibits P450P4502E1
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Figure 1.8. Metabolism of 1,2-dichloroethane showing two activation pathways. P450
2E1 leads to 2-chloroacetaldehyde while GST results in CEG. Adapted from
Williams, 1994.20
metabolism, resulted in an increase in hepatotoxicity that was not observed for DCE
treated rats alone (Igwe, et al., 1986) and an increase in DCE blood levels 5-fold over
controls (Cheever, et al., 1990). Although in rats the oxidative and conjugation routes
occur at a ratio of 4:1 (van Bladeren, et al., 1981b), data strongly implicate the GSH
pathway having greater importance regarding carcinogenicity and mutagenicity (Storer
and Conolly, 1985; Romert, et al., 1990; Ballering et al., 1993). When DCE is
conjugated with GSH the product is S-(2-chloroethyl)glutathione (CEG). CEG has
been detected in the bile, by HPLC analysis, of rats treated with BCE (Marchand and
Reed, 1989). CEG, and not the cysteine conjugate, is responsible for the
nephrotoxicity and proximal tubular lesions observed in rats (Kramer, et al., 1987).
CEG was shown by Jean and Reed to be capable of alkylating a variety of functional
groups present in amino acids, in particular, the sulthydryl functionality on cysteine,
the hydroxyl group on tyrosine and the imidazole of histidine (Jean and Reed, 1989).
Much of my thesis research has focused on identifying the sites of alkylation in the
peptide oxytocin, human hemoglobin and E. coli thioredoxin following alkylation by
CEG (Erve, et al., 1995a; Erve, et al., 1995b).
Biological Mass Spectrometry
In a recent review of mass spectrometry, it was stated that:"This is the era of
biological mass spectrometry, the study of macromolecular science in the overall
context of human health and disease" (Burlingame, et al., 1994). Biological mass
spectrometry is reliant on the capability to ionize large, polar biomolecules, such as,
proteins, nucleic acids, carbohydrates and complex lipids. The strength of biological
mass spectrometry, relative to other advanced techniques including nuclear magnetic
resonance spectroscopy and X-ray crystallography, is the capability to analyze
mixtures and obtain accurate molecular weight and structural information on small
(picomole and lower) amounts of sample.21
Several ionization strategies exist to introduce charged biomolecules into the
mass spectrometer for analysis. One of the first developed was fast atom
bombardment (FAB), which permitted the mass spectrum of met-lys-bradykinin (Mr
1318) to be recorded in 1981 by Barber and coworkers. FAB employs a beam of
atoms (eg. argon or xenon) or ions (eg. cesium) accelerated to kinetic energies on the
order of several keV, which collide with sample molecules present in a liquid matrix,
typically glycerol. Depending on the chemical nature of the compound, either positive
or negative molecular ions are formed in the gas phase and the mass to charge ratio
(m/z) of the compound can be measured. One disadvantage of FAB ionization is the
creation of a large number of glycerol ions that can obscure the molecular ion of
interest. In addition, for peptide mixtures, FAB will often preferentially ionize
hydrophobic peptides to a greater extent than hydrophilic peptides (Biemann, 1988).
Two ionization techniques have dominated the field of biological mass
spectrometry in the past five to six years. One ionization technique is called
electrospray, or when nebulization is utilized to assist droplet formation, ionspray.
The combination of electrospray ionization with mass spectrometry has been credited
equally to two different groups: Fenn and Yamashita in the US and Aleksandrov in
the former USSR (Smith, et al., 1990). The general basis of electrospray ionization is
the initial dispersal of multiply charged liquid droplets followed by evaporation of the
liquid to produce multiply charged analytes. A high electric potential, typically 3-6
kV, in the region where the analytes elute from a capillary column, leads to a fine
mist of highly charged drops containing analyte. Evaporation of the liquid drop is
assisted by a counterflow of heated, dry gas, until the drop is so small that a columbic
explosion occurs as a result of many like charged molecules present close together
(Smith, et al., 1990). This produces molecular ions containing multiple charges which
are introduced into the mass spectrometer; the mass spectrum can be described as
consisting of a distribution of charged species (Figure 1.9), each representing a
different m/z of the compound of interest. Because of this multiplicity in m/z,
electrospray ionization enables the molecular weight of proteins to be measured with100
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Figure 1.9. Electrospray mass spectrum of E. coli thioredoxin obtained on a Sciex III
plus triple quadrupole instrument.
high precision: 11,667.4±1.9 for E. coli thioredoxin (Mr 11,668). Matrix-assisted laser
desorption-ionization is the other technique that has had major impact on the mass
spectrometry of biomolecules. Tanaka and, independently, Hillenkamp, are attributed
with pioneering the idea of dispersing the sample in a radiation absorbing matrix
(Burlingame, Boyd and Gaskell, 1994). Laser radiation (266 nm) was used in the
experiments of Hillenkamp to irradiate a sample present in nicotinic acid, resulting in
desorption of molecular ions up to molecular weight 60 kDa (Biemann, 1988). To
overcome the broad peaks characteristic of the ion signals produced with nicotinic23
acid, cinnamic acid derivatives were tested and found to have the advantage of less
matrix protein-adduct formation. The matrix of choice for many applications is now
3,5-dimethoxy-4-hydroxycinnamic acid (sinnapinic acid); it absorbs at 355 nm in the
ultraviolet (Beavis and Chait, 1990). Time of flight mass spectrometers are the ideal
mass analyzers when ionization, such as produced by a pulsed Nd:YAG laser, occurs
in pulses.
The sequence of basic units in a biopolymer is important information that can
give insight into the function of the biological compound in question. For peptides
and proteins, the basic units are amino acids linked together by peptide bonds. As all
the ionization processes described above are "soft" ionization methods, they generally
produce singly or polyprotonated molecular ions that contain too little energy to
fragment (Biemann, 1988). Tandem mass spectrometry (MS/MS) is a powerful
technique that allows structural information on peptides, and hence proteins, to be
obtained by a process known as "collision-induced dissociation" (OD) (Hunt, et al.,
1986). By passing a selected molecular ion into a collision cell filled with an inert
gas, such as helium or argon, peptide bonds will fragment to produce "product ions"
that are mass analyzed in a second mass spectrometer. Nomenclature that identifies a
product ion based on whether the C-terminus (y ion) or N-terminus (b ion) carries the
charge was developed by Roeppstorf and Fohlman (Roepstorff and Fohlmann, 1984),
and modified by Biemann ( Biemann, 1988) (Figure 1.10). A limited number of
sequences for the peptide can be deduced based on the diagnostic b and y ion series
observed. The utility of MS/MS in structure elucidation is illustrated by the
determination of the complete primary structure of thioredoxin from Chromatiurn
vinosum by sequencing the peptides obtained by Cryptic digestion (Johnson and
Biemann, 1987). Recent work has attempted the direct sequencing of protein with
masses as high as 66 kDa by CID (Loo, et al., 1991). However, the complexities
caused by the formation of multiply charged product ions makes sequence information
difficult to glean from the spectra and further progress, both theoretical and
instrumental, is needed before this strategy for protein sequencing becomes common.24
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Figure 1.10. Nomenclature for fragment ions obtained during CID.
Some applications of MS/MS in toxicology have been reviewed by Blair (Blair,
1993). These include structural characterization of proteins and peptides covalently
modified by xenobiotics, screening of GSH-conjugates of drugs, identification of drug
metabolites and reactive intermediates. MS/MS has been applied to identify the nature
of carcinogen-DNA adducts derived from polycyclic aromatic hydrocarbons (PAHs).
It has been assumed that PAHs are activated by P450s to the diol-epoxide, the ultimate
carcinogen, that reacts with DNA.. An alternative mechanism is one electron oxidation
to form a radical cation; reaction with DNA bases will form an adduct unique to this
mechanism (RamaKrishna, et al., 1992). Gross and coworkers first obtained evidence
consistent with the radical cation mechanism by in vitro activation of benzo[a]pyrene
with either electrochemical oxidation, horseradish peroxidase, or P450s, and structural
characterization of the modified bases by MS/MS (Wellemans, et al., 1994). In vivo
evidence for the radical cation mechanism will depend on the ability to measure
adducts in the femtomole range and requires new and more sensitive mass
spectrometric detection procedures, such as, array detectors with multichannel
capability.25
Summary of Objectives
1. To examine the alkylation chemistry of CEG towards peptides and proteins in
order to determine the extent to which adducts are formed in vitro.
2. To apply tandem mass spectrometry to identify particular amino acids in these
peptides and proteins that undergo alkylation by the reactive species CEG.
3. To investigate the influence of protein tertiary structure in influencing which amino
acids are targeted by the reactive species CEG.26
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Abstract
S-(2-chloroethyl)glutathione (CEG), an alkylating agent formed by glutathione
conjugation with 1,2-dichloroethane (DCE), is able to alkylate DNA and proteins. As
a prelude to identification of specific protein alkylation sites, the peptide oxytocin was
alkylated by CEG, and tandem mass spectrometry was used to identify the alkylation
sites.It was found that mono-, bis- and tris- adducts can result from alkylation of
reduced oxytocin and that tandem mass spectrometry differentiated (S- [2- (cys)'ethyl]
glutathione)oxytocin (mono adduct Cys-1) from (S-[2-(cys)6ethyl]glutathione)oxytocin
(mono adduct Cys-6). Manual Edman degradation was used to eliminate the possibility
that alkylation has occured at Tyr-2 rather than at Cys-1 in the case of (S42-
(cys)14ethyl]glutathione)oxytocin (bis adduct) and mono adduct Cys-1. A mono-
adduct-homo-dimer resulting from alkylation at Cys-6 and disulfide bridge formation
through Cys-1 was also identified. Oxidized oxytocin formed two minor adducts,
representing less than 5% of the oxytocin present in the reaction mixture. These
findings demonstrate that alkylation of oxytocin by the episulfonium ion of CEG did
occur, as evidenced by tandem mass spectrometry, and that characterization of these
adducts will aid in the identification of alkylated amino acids in proteins exposed to
CEG.28
Introduction
It is now widely accepted that reduced GSH functions not only to detoxify
xenobiotics but can also enhance the toxicity of certain chemicals through the
formation of reactive GSH conjugates (Dekant and Vamvakas, 1993; Monks, et al.,
1990; Monks and Lau, 1994). The dihaloalkanes are metabolized by both microsomal
and GSH transferase (GST) enzyme activity (Guengerich, et al., 1980; van Bladeren,
et al., 1981b), but it is thought that the latter pathway is more important with respect
to mutagenicity (van Bladeren, et al., 1981a). The conjugation of a dihaloethane
(DHE) with GSH by GST, results in the formation of a sulfur half-mustard, S-(2-
haloethyOGSH (Rannug, et al., 1978; Shi and Hill, 1981). The sulfur half-mustard
forms a putative episulfonium ion which is a reactive alkylating agent.It has been
shown in vivo that the S- (2- chloroethyl)GSH conjugate of dichloroethane (DCE) is
found in the bile of rats dosed with bromochloroethane (BCE) (Marchand and Reed,
1989). The GSH conjugate of 1,2-dichloroethane has also been found to cause a high
mutation frequency in Salmonella typhimurium due to adduct formation at the N7
position in guanine (Humphreys, et al., 1990). The GSH conjugate of 1,2-
dibromoethane has been identified as an adduct on guanine and is thought to be
responsible for the high degree of mutagenicity of this compound (Guengerich and
Ozawa, 1983).
Many chemical carcinogens are electrophilic and are capable of reacting with
nucleophilic sites in proteins (Skipper and Tannenbaum, 1990). For certain chemicals,
a relationship has been found between the degree of DNA alkylation and protein
alkylation (Ehrenberg and Osterman-Golkar, 1980). This has found application in
biomonitoring exposure to environmental chemicals in the work place (Farmer, et al.,
1986). Measuring the differences in degree of alkylation by S-(2-chloroethyl)
glutathione (CEG) among a variety of dipeptides can give quantitative data on the
relative reactivity among functional groups (Jean and Reed, 1989), but it is expected
that reactivity of a particular functional group present in a protein will behave
differently due to steric or electrostatic factors.It has been reported, for example, that29
the predominant alkylation sites in hemoglobin following alkylation by styrene oxide
are at histidine a-20 and P-143 as opposed to the more nucleophilic 13-93 cysteine
(Kaur, et al., 1989). Consequently, it would be useful to have an analytical technique
to answer the question of which amino acid(s) CEG has alkylated on an adducted
protein.
Mass spectrometry, including fast atom bombardment (FAB/MS) and, more
recently, ionspray MS, is a powerful technique for characterizing modifications on
proteins including post translational modifications such as glycosylation (Svoboda, et
al., 1991), phosphorylation (Biemann and Scoble, 1987) as well as alkylation (Kaur, et
al., 1989). Tandem mass spectrometry allows sequencing of peptides at the femtomole
level by collisionally induced dissociation (CID) of the peptide in the mass
spectrometer (Amott, et al., 1993). Therefore, it is possible by mass spectrometry to
determine not only the presence of a modification, but the particular amino acid
modified as well.
One strategy for determining sequence information in proteins is to
enzymatically digest the protein using specific proteases, and to analyze the resulting
peptide digest by mass spectrometry in a procedure known as peptide mapping. This
technique was applied to the characterization of hemoglobin variants (Jensen, et al.,
1991) and to locate disulfide bonds (Morris and Pucci, 1985). The purpose of this
investigation was to characterize the structure of a peptide covalently modified with
the alkylating agent CEG by tandem mass spectrometry, and to understand better the
fragmentation patterns of this alkylated peptide during the OD process. The
knowledge gained here should aid in the peptide mapping experiments of proteins
modified by CEG. To this end, we selected the peptide, reduced oxytocin, which has
been used previously by others to examine the acylation chemistry of S-(2-
chloroacetyl)glutathione (Liebler, et al., 1988), and the carbamoylation chemistry of S-
(N-methylcarbamoyl)glutathione (Pearson, et al., 1991). The objectives of the present
study were to identify which amino acids in oxytocin undergo alkylation at
physiologic temperature and pH.30
Materials and Methods
Chemicals. Oxytocin (95%) was purchased from Calbiochem-NovaBiochem
(La Jolla, CA). Reduced glutathione (GSH), phenylisothiocyanate (PITC), 4,4'-
pyridine disulfide (PDS) and trifluoroacetic acid (TFA) were purchased from Sigma
(St. Louis, MO). BCE was purchased from Aldrich (Milwaukee, WI).
tris-(2-Carboxyethyl)- phosphine (TCEP) was obtained from Pierce (Rockford, IL).
Pyridine was from Mallinckrodt (St. Louis, MO). HPLC solvents were purchased
from J. T. Baker (Phillipsburg, NJ), and 18 megohm water was prepared by a Milli -Q
sytem (Waters, Bedford, MA ).
Synthetic Procedures. CEG was synthesized according to the method of Reed
and Foureman (Reed and Foureman, 1986). CEG, purified by preparative HPLC,
contained at most 5% of the hydrolysis product S-2-(hydroxyethyl)glutathione (HEG)
as estimated by FAB/MS. The CEG was stored as a lyophilized powder under argon
at -80 °C. The alkylating capability of CEG to thiols was assessed by a
spectrophotometric technique with 4,4'-dithiopyridine (PDS). PDS permits the
determination of sulfhydryl groups in simple compounds (Grassetti and Murray, 1967)
and has been used to monitor the disappearance of free sulfhydryl groups in
hemoglobin following exposure to alkylating agents (Neis, et al., 1984). Briefly, CEG
was reacted with reduced GSH in ammonium bicarbonate buffer at pH 7.4. The thiol
concentration was then determined by adding PDS and measuring the absorbance at
324 nm of the resulting 4-thiopyridone. CEG at five fold molar excess over GSH
reduced the free thiol concentration by approximately 90%. The hydrolysis product,
HEG, did not affect GSH thiol status and was used as a negative control.
Reduction of Oxytocin by TCEP. Oxytocin was reduced with a phosphine
derivative, TCEP. In a typical alkylation experiment, two hundred micrograms (0.2
pmol) of oxytocin was weighed into a 1.5 mL Eppendorf centrifuge tube.It was
reduced, by addition of 200 pi, of 4 mM TCEP (8 fold molar excess) and incubation
for 10 minutes, to yield a 1 mM solution of reduced oxytocin. Disulphides are
reduced by TCEP via a mechanism similar to that of the trialkyl phosphines, which31
probe reduction of bovine insulin prior to matrix assisted laser desorption mass
spectrometry (Fisher, 1993). The advantages of TCEP include its high solubility in
water, activity below neutral pH, selectivity towards disulfide bonds, and small molar
excess needed to quantitatively reduce disulfides (Bums, 1991). TCEP is superior to
dithiothreitol (DTT) in this experiment because of the need to either extract excess
DTT from oxytocin, or to add CEG in molar excess above DTT. In the latter case,
the chromatogram of the resulting reaction mixture is very complex, presumably due
to CEG reacting with DTT to give a variety of products. In contrast, reaction
mixtures of oxytocin reduced with TCEP do not contain other products.
Covalent Modification of Oxytocin by CEG. Aliquots of reduced oxytocin
(50 !IL) were placed in separate Eppendorf tubes and 50 1.1L 0.4M ammonium
bicarbonate buffer (pH 7.7) was added. CEG was weighed and dissolved in 40-70 I.LL
buffer and quickly added to the oxytocin to give molar ratios ranging from equimolar
to 30 fold excess (CEG vs. oxytocin). The pH dropped slightly with the addition of
CEG so that the pH of the reaction mixture was between 7.0- 7.4. The reaction
mixture thus consisted of approximately 0.5 mM oxytocin and from 0.5 to 15 mM
CEG. The reaction mixtures were incubated for 90 minutes at room temperature to
insure that the full alkylating capacity of CEG was utilized. The reaction mixture was
then injected onto an HPLC column and adducts were collected as described below.
Instrumentation. Isolation of the oxytocin CEG adducts was accomplished by
reverse phase HPLC with an analytical C18 column (250 x 4.6 mm, 5 gm, 30
Angstroms, Vydac, Hesperia, CA).The elution gradient was linear from 15% B to
30% B in 17 minutes with a flow of 1 mUmin [solvent A = CH3CN/H20/1114A (5:95:1
v/v/v); solvent B = CH3CN/H20/TFA (80:20:0.8 v/v/v)]. However, to increase
separation between closely eluting adducts, the gradient was held constant prior to the
elution of the more closely spaced adducts. This allowed baseline resolution to be
obtained for most of the adducts. Mobile phases were prepared from HPLC grade
solvents and Milli -Q water and purged for 15 minutes with helium gas prior to use.
The liquid chromatography system included a Spectra Physics Series 8800 pump
(Freemont, CA), an Applied Biosystems 759 UV absorbance detector set for 215 nm,32
an Hewlett-Packard 3388A integrator/recorder, a dynamic mixer, and a column heater
to maintain a temperature of 29° C. Adducts were collected manually and concentrated
by roto-evaporation prior to mass spectrometric analysis.
Sequencing of oxytocin-adducts was accomplished with a Perkin-Elmer Sciex
API III plus triple-quadrupole mass spectrometer (Sciex, Thornhill, Canada). Samples
were introduced into the mass spectrometer by infusion at a rate of 1.2-2.5 tiIimin
with a syringe pump (Harvard Apparatus, South Natick, MA) and a solvent mixture of
CH3OH/H20/formic acid (50:50:1 v/v/v) via an injector fitted with a 5 tiL sample
loop. Collision induced dissociation (CID) took place in the second quadrupole (RF
only), with argon as a collision gas at a thickness of 2.7-3.4 x 10'4 molecules/cm2.
The ion spray voltage was 5000 V and the orifice voltage was varied between 60 and
90 volts depending on the adduct. Collision energies were optimized for each adduct
and ranged from 16 eV (laboratory frame of reference) for the mono-adducts to 26 eV
for the bis-adduct. The mono-adduct-homo-dimer was fragmented at 37 eV.
FAB/MS was performed on a Kratos MS-50 double focussing instrument
operated at a resolution of 1000 for raw data collection. A 2 }IL sample volume was
mixed on the probe tip with 2 1..iL of matrix consisting of thioglycerol/glycerol (2:1
v/v). Xenon gas was used to generate the primary ionizing beam from an Ion-Tech ion
gun operated at 7-8 kV.
Edman Degradation. Samples were reduced to a volume of 5 !IL or less in a
0.6 mL Eppendorf tube. Five microliters of a 5% solution of PITC in pyridine was
added to each adduct, and the mixture allowed to react for 30 minutes at 45° C after
which the products were roto-evaporated. Samples were then hydrolyzed with neat
TFA at 37° C for ten minutes and roto-evaporated again. Prior to FAB/MS analysis
the samples were reconstituted with 1 [it of acetic acid and 5 pi, water.33
Results
Alkylation of oxytocin by CEG. The reduced form of oxytocin has two
cysteinyl sulfhydryl groups, a hydroxyl group on tyrosine, three primary amides anda
terminal primary amino group that are potential nucleophiles (Figure 2.1). The
alkylated forms of oxytocin were separated by HPLC due mainly to their differences
in polarity. The order of elution of the adducts is tris, bis-,mono Cys-6, and mono
Cys-1. These all elute prior to reduced oxytocin. The mono-adduct-homo-dimer eluted
after reduced oxytocin, presumably because of its higher molecular weight.
Differences between the distribution of the alkylated oxytocins can beseen as the
amount of CEG is increased. When adding an equimolar amount of CEG to reduced
oxytocin, there was approximately 8% bis-adduct, 11% mono adduct at cysteine-6, and
35% mono adduct at Cys-1 compared to 45% unreacted oxytocin. As expected,
increasing CEG to give a five fold excess over oxytocin results in a much greater
amount of bis adduct (39%). However, the relative abundance of the mono adduct
cysteine-6 becomes greater (30%) than that at Cys-1(16%), compared to 8% reduced
oxytocin (Figure 2.2). Above 15-fold excess, some tris adduct was detected although
most of the adducted oxytocin was the bis adduct. The tris alkylated form was never
predominant.
When the reaction mixtures were exposed to air for extended periods of time,
some of the reduced oxytocin would reoxidize or polymerize. The mono adducts,
which still had a free sulfhydryl group, would, to a certain degree, form intermolecular
disulfide bonds. There is tandem-MS evidence that the resulting product isa homo-
dimer linked between Cys-1, with the CEG adduct on Cys-6 (Figure 2.3).It is
possible that another homo-dimer linked via Cys-6 exists because another HPLC peak,
poorly resolved from the Cys-1 homo-dimer, was observed. However, we were unable
to acquire mass spectral data to support this possibility.34
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Figure 2.2. HPLC analysis of reduced oxytocin and its adducts for (A) an equimolar
mixture of CEG:oxytocin and (B) a 5:1 molar mixture of CEG:oxytocin. Peaks are as
follows:(a) bis-adduct; (b) mono-adduct Cys-6; (c) mono adduct Cys-1; (d) reduced
oxytocin; (e) mono-adduct-homo-dimer. Chromatograms represent the elution of 215
nm absorbing material from the reverse phase column as described in Materials and
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Mass Spectrometry
Spectra of the alkylated forms of reduced oxytocin were obtained by both
FAB/MS and ionospray MS. FAB/MS revealed peaks at m/z 2009 (Iris), m/z 1676
(bis) and m/z 1343 (monoXdata not shown). Ionspray MS produced both the singly
and doubly charged forms of the mono- and bis-adducts, with the doubly charged
forms predominating. The tris-adduct formed a triply charged ion in addition to a
doubly charged ion.Since neither of these techniques provided sequence information,
tandem MS was used to address that question.
The daughter ion spectrum of reduced oxytocin has been recorded by Pearson
et al. with FAB/MS/MS (Pearson, et al., 1991). CID spectra of peptides are
distinguished by a series of b and y fragment ions that provide amino acid sequence
information about the peptide (Biemann, 1988). Noting which peaks in the spectra of
the alkylated forms of oxytocin shifted compared to unalkylated oxytocin helped to
establish the sites of CEG adducts as described below.
Daughter ions of adducts were produced by fragmenting the doubly charged
parent ion. Most spectra revealed a partial set of bn ions, revealing the sequence from
the N-terminus to the C-terminus and an almost complete set of complementary yn
ions, revealing the sequence from the C-terminus to the N-terminus. The y3 ion was
prominent and observed in all the spectra (Figures 2.3, 2.4 and 2.5), due to cleavage of
the sequence Pro-Leu-Gly from the C-terminus. Since the regions of the spectra
below y3 (m/z 285) were almost identical, it follows that no alkylation occurred on
these three amino acids.
One mono adduct had an HPLC retention time of approximately 21.7 min, and
displayed an ion at m/z of 1058, that was shifted by the mass of CEG moiety (334
Da) above the b6 ion at m/z 725 in unalkylated oxytocin, indicating alkylation
somewhere on the first six amino acids. Further analysis of the spectra revealed that
y4 through y7 and y9 were also shifted 334 Da, indicating that alkylation occurred at
Cys-6 (Figure 2.4B). The other mono adduct eluted with a retention time of
approximately 23.5 min, had the identical molecular weight, and also contained a
shifted b6 ion at m/z 1058, but b3 through b5 were also shifted 334 Da while y138
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through y7 were not (Figure 2.4A). This condition can only be satisfied if alkylation
had occurred at either Cys-1 or Tyr-2. As for native oxytocin, this mono adducts
shows little indication of fragmentation between these two residues to produce a b1 ion
(m/z 437) or the corresponding y8 ion (m/z 906) (Figure 2.4A). This made
unambiguous assignment of the alkylation site impossible, and it was necessary to
perform a manual Edman degradation to confirm that Cys-1 was alkylated.
Comparison of the spectra for both mono adducts reveals clear differences in the peaks
that are present, which reflect their different structures (Figure 2.4).
Although the triply charged ion at m/z 895 was more intense, sequencing of the
mono-adduct-homo-dimer was accomplished by fragmenting the doubly charged ion at
m/z 1342, as this produced a more readily interpretable spectrum containing primarily
singly charged ions. The spectrum exhibited a complete set of yn ions, but no bn ions
were identified (Figure 2.3). The peak at m/z 1374 corresponds to the intact mono
adduct plus both sulfur atoms involved in the disulfide bond. The peak at m/z 1720
corresponds to the intact mono adduct plus the amino acids Cys-Tyr-Ile from the other
mono adduct. Peaks at m/z 1849 and 1963 reflect additions of the masses of Gln
(128) and Asn (114) to m/z 1720, respectively. The highest m/z value at 2399
corresponds to one complete mono adduct plus six amino acids of the other mono
adduct, including the alkylating moiety. This ion appears to lose a glutamate residue
as indicated by the peak at m/z 2270. Support for the disulfide linkage was obtained
by adding the reducing agent TCEP to the dimer, which resulted in its disappearance
and simultaneous appearance of the monomer (spectra not shown).
Alkylating oxidized oxytocin with 25 fold molar excess CEG produced an
adduct eluting immediately before oxidized oxytocin in an HPLC run, with an area
approximately 5% that of oxidized oxytocin (data not shown). Although not evident
from the chromatogram, this peak was due to two adducts when analyzed by ionspray
MS. The two pairs of singly and doubly charged species corresponded to the mass of a
mono alkylated (m/z 1341) and bis-alkylated (m/z 1674) form of oxidized oxytocin,
respectively.41
The CID spectrum (data not shown) of mono-alkylated oxidized oxytocin
revealed a pattern similar to that of mono adduct Cys-1. Differences include a peak at
m/z 1007 that corresponds to oxidized oxytocin. This forms by the loss of the intact
alkylating, which is seen at m/z 334, from the parent ion. The ions in the spectrum
are consistent with alkylation at the N-terminal cysteine. Since the sulfhydryl groups
exist as a disulfide bond, alkylation must have occurred at the free amino terminus.
Sequencing the bis-adduct of oxidized oxytocin produced the daughter ion
spectrum that is very similar to that of the bis adduct of reduced oxytocin, which is
shown in Figure 2.5. The highest value m/z, 1389, observed in the spectrum of the
oxidized bis adduct (Figure 2.5, insert) corresponds to the b6 ion; the b6 ion in the
daughter ion spectrum of bis alkylated reduced oxytocin appears at m/z 1391, i.e. two
mass units higher. The peak at m/z 1260 corresponds to b6-Glu, also analogous to
what is observed in the reduced bis adduct. The prominent peak at m/z 1341 (Figure
2.5, insert), absent in the bis-adduct spectrum of reduced oxytocin, is explained as the
loss from y9 at m/z 1674 (not in insert) of an intact alkylating moiety seen at m/z 334
amino group of cysteine or the hydroxyl of tyrosine and the adduct. This could result
from cleavage of the carbon-nitrogen bond between the free amino group of cysteine
or the hydroxyl of tyrosine and the adduct. This ion goes on to lose a glutamate
residue from the other alkylating moiety to produce the peak at m/z 1211. Another
peak also explained by loss of the complete alkylating moiety is m/z 927 (not in
insert), which arose from b6-Glu.
Removal of N-terminus by manual Edman Degradation.
Several adducts were subjected to manual Edman degradation to provide
additional structural information that was absent in the CID spectra In particular, the
absence of the b1 ion and the complementary y8 ion for the bis and mono Cys-1
adduct leaves open the possibility that the spectra could be explained by tyrosine
alkylation. Edman degradation specifically removes the N-terminal amino acid from a
protein, resulting in the formation of a phenylthiohydantoin derivative of the cleaved
amino acid and a truncated peptide (Allen, 1989). If it is blocked at the N-terminus,
by acetylation or alkylation, for example, the Edman reaction cannot occur. Removing42
the alkylated cysteine from the bis adduct gave a peak at m/z 1239, which is
consistent with a truncated oxytocin with one alkylating moiety at Cys-6. Similarly,
removing the N-terminal amino acid from the mono adduct assigned to Cys-1 gave the
same m/z as observed for the Edman degradation product of unalkylated oxytocin,
which cannot be explained if alkylation had been at Tyr-2. Furthermore, this supports
location of the alkylating moiety on the sulfhydryl group of cysteine and not on the
free amino terminus; for reason explained above, alkylation on this latter site would
block removal of the N-terminal cysteine. Removal of the N-terminus from the mono
adduct assigned to Cys-6 also gave a peak at m/z 1239, which is consistent for this
structure (Table 2.1). Thus, cleavage of the N-terminal cysteine from both adducts
provided information that was consistent for the structures of the adducts proposed.
In addition, we took both the mono adduct at Cys-1 and bis-adduct and added
iodoacetamide (IAA) which is known to react exclusively with free thiols. In
agreement with assignments, the mono adduct added one molecule of IAA while the
bis-adduct did not react with IAA. Therefore, the mono adduct at Cys-1 has one free
thiol while the bis adduct has no free thiols.
Table 2.1 Edman degradation results for oxytocin and adducts.
Compound Initial (m/z) Edman d (m/z) P1TC a (m/z)
Oxytocin 1009 906 (-103) 1041b
Mono-Cysl 1343 906 (-437) 1041
b
Mono-Cys6 1343 1239
b(-103)
1374
Bis adduct 1676 1239b( -437) 1374
GSH 308 n.d. C n.d.c
HEG 352 n.d.c 487 b
S-Ethyl GSH 336 n.d.c 471b
a Addition of PITC (135 amu) to degradation product.
b Signifies major peak
c Not detected
dMeasured m/z following Edman degradation. Enclosed in parenthesis
is the mass of the residue removed.43
Discussion
The results of this in vitro study confirm expectations that CEG is a chemically
reactive species capable of alkylating nucleophilic sites in peptides at physiological pH
and temperature. The focus of the present investigation was to define better the
alkylation chemistry by identifying which amino acids became alkylated and to
determine the behavior of CEG alkylated peptides during the cup process. Reaction
of reduced oxytocin with CEG resulted in the formation of a total of five different
adducts which were sequenced by tandem mass spectrometry. Free sulfhydryl groups
in oxytocin appear to be the main site of alkylation in reduced oxytocin, since the bis-
adduct and both mono-adducts contain the alkylating moiety(ies) on the sulfhydryl of
cysteine.It was apparent from the HPLC data that the mono adduct at Cys-6 was
formed in preference to the mono adduct at Cys-1 at levels of CEG greater than five
times that of oxytocin. This is in agreement with the report of Pearson et al. (22) for
N-(S-methyl)carbamoyl GSH, namely, the preferential carbamoylation of the internal
cysteine (Cys-6).Baillie and Davis also report that this internal cysteine is the site of
disulfide formation with GSH (Baillie and Davis, 1993). However, with an equimolar
level of CEG to reduced oxytocin, the data show clear evidence for modification at the
N-terminal cysteine (Cys-1), and this species is more abundant than the mono adduct
at Cys-6. The data for the mono-adduct- homo-dimer is compatible with two mono
adducts alkylated at Cys-6 and joined by a disulfide bridge through Cys-1. Although
this product was never a major component, it was often present and could be easily
detected during the HPLC runs.
Fragmentation of glutathione conjugates have been reported at both high and
low collision energies (Baillie and Davis, 1993; Ballard, et al., 1991; Murphy, et al.,
1992). Loss of a glutamate residue, or a glycine residue derivatized to the methyl
ester has been used as a screening procedure to detect the presence of glutathione
conjugates in the bile of rats (Ballard, et al., 1991; Pearson, et al., 1990). In the CID
spectra reported here, loss of both a glycine residue and a glutamate residue from the
alkylating moiety could be seen giving rise to a subseries of ions 75 or 129 mass units44
below their respective b or y ions, as tabulated for the bis-adduct in Table 2.2.
Intensities of these ions were often comparable, and for certain ions, greater than the
parent b or y ion. For example, the b2 ion at m/z 600 in the bis adduct spectrum
generates an ion at m/z 525 that is twice as intense. As the bis-adduct contained two
alkylating moieties, up to two glutamate residues could be lost from a given ion as
seen in Table 2.2; this was observed for y7 and y9. The y9 ion of the Iris adduct lost
three glutamate residues. Loss of glutathione was also detected, but the glutathione
fragment was not a prominent ion. Rather, loss of a glutamate residue from the
glutathione fragment was detected as an intense peak at m/z 177 in the spectra of both
bis-adducts, the homo dimer and the oxidized mono adduct.
Oxidized oxytocin also reacted with CEG to give at least two adducts that were
sequenced by tandem mass spectrometry. Although these spectra were similar to those
of mono adduct Cys-1 and the bis adduct of reduced oxytocin, there were differences.
Because oxidized oxytocin contains no free thiols, the number of possible alkylation
sites are reduced. The similarity between the spectra of mono Cys-1 of the reduced
oxytocin adduct with the mono oxidized adduct suggests that CEG is reacting at the
amino terminus of Cys-1. The presence of a bis-adduct of oxidized oxytocin, albeit in
low abundance, implies that CEG can react with another nucleophile. The data for the
bis-adduct support alkylation at Tyr-2 in addition to Cys-1, based on the observation
of yry7 ions which are not shifted with respect to unalkylated oxytocin. This is
consistent with seven unmodified amino acids from the C-terminus. The y8 ion was
not observed, which may suggest that it has been shifted due to alkylation, and is
fragmenting to ions that have not been identified. Tyrosine in the peptide angiotensin
has been shown to be a target of alkylation following treatment with styrene oxide
(Ferranti, et al., 1992). During mass spectrometry both adducts of oxidized oxytocin
showed the loss of a complete adduct, something that was not detected in the spectra
of the adducts formed with reduced oxytocin. This may be due to an alternative
fragmentation mechanism between the adduct and a nucleophilic nitrogen or tyrosine
hydroxyl that is broken in the CID process, which does not occur with the bond
between the adduct and sulfur.45
Table 2.2. Product ions for the bis-adduct, showing loss of glutamic acid and/or
glycine from CEG.
bn predicted bn observed bn -glutamatea-glycineb
(m/z) (m/z)
1 437.1 n.d.
2 600.2 n.d.
3 713.3 712.7 +
4 841.3 841.1 +
5 955.4 955.1 + +
6 1391.5 1391.0 +
7 1488.5 n.d.
8 1601.6 1601.0 + +
9 1658.6 1658.0 + +
yn predicted yn observed yn -glutamatea-glycineb
(m/z) (m/z)
1 75.1 74.9 n.a. n.a.
2 188.1 188.0 n.a. n.a.
3 285.2 285.2 n.a. + (Gly9)
4 721.3 721.5 + +
5 835.3 834.5
6 963.4 963.2 +
7 1076.5 1076.5 -H- -
8 1239.6 n.d.
9 1675.6 1676.0 -H- +
a Loss of glutamic acid is denoted by +; no loss, by-.
b Loss of glycine is denoted by +;no loss, by -.
n.a. not applicable
n.d. not detected46
The Edman degradation results support the assignment of the alkylation sites
for the bis-adduct and both mono adducts of reduced oxytocin. Removal of the N-
terminus of mono-adduct Cys-1, gives the same mass as observed when Edman
degradation is applied to reduced oxytocin. This would not have been observed if
tyrosine were alkylated. For each of the adducts and oxytocin, it was observed in the
FAB/MS spectra that there was a peak corresponding to an addition of 135 Da, the
mass of PITC. Thus, the major peak in the FAB/MS spectrum of the Edman product
of oxytocin was not at m/z 906 (oxytocin-Cys) but at m/z 1041, which corresponds to
the addition of PITC (+135 amu). Sequencing of this peptide by OD revealed that
PITC had added to the free thiol of Cys-6. It is not apparent why PITC can add to
both S-ethyl GSH and the hydrolysis product of CEG, namely HEG, and not to the
alkylating moiety on the oxytocin adducts.
One requirement of tandem MS as a method for adduct characterization is the
necessity of optimizing the fragmentation energy for each adduct to obtain a product
ion spectrum. Since the optimal collision energy for the two mono-adducts was not
the same as that for the bis-adduct nor that for the tris-adduct, tuning of the instrument
was required. An important aspect to the mass spectrometric sequencing of the CEG-
alkylated oxytocins was that neither the b1 nor y8 ion appeared, making the
unambiguous assignment of alkylation at Cys-1 or Tyr-2 by tandem-MS impossible.It
was necessary to perform a manual Edman degradation step to answer this question.
Nevertheless, using previous knowledge of the alkylating properties of CEG, one can
deduce where the most likely site of alkylation is when faced with two possibilities.
The strengths of this method are that, although fragmentation of the adduct occurs, the
bond between cysteine, the major target of CEG, and the ethylene bridge derived from
CEG to the alkylated amino acid does not fragment, allowing identification of
alkylation sites on small amounts of sample.
The information provided in this study should help in solving the more difficult
task of identifying alkylation sites in proteins. For example, the partial fragmentation
of the alkylating moiety derived from CEG could allow for neutral loss screening to
identify an alkylated peptide in a mixture of peptides produced in a protein digest.47
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Abstract
Alkylation of reduced Escherichia coli thioredoxin by the episulfonium ion
derived form S-(2-chloroethyl) glutathione (CEG) at physiologic pH resulted in at least
three different alkylation products. These adducts were separated byreverse phase
chromatography, digested with trypsin, and peptide-mapped. The peptide containing
the active site cysteines was collected and sequenced by tandemmass spectrometry.
Results indicate that the site of alkylation was at Cys-32 exclusively withno alkylation
at Cys-35. Raising the pH above the plc of Cys-35 to ionize the thiol before reacting
with the episulfonium ion of CEG did not lead to alkylation at Cys-35, suggesting that
a steric factor prevents the episulfonium ion of CEG from accessing this cysteine. A
tryptic digest of a minor bis-adduct yielded an alkylated peptide which contained
tyrosine, also known to be alkylated by CEG. Sequencing by tandem mass
spectrometry, however, was unsuccessful due to fragmentation of the alkylating moiety
from the peptide. Results of this study confirm that the episulfonium ion of CEG can
adduct thioredoxin at the active site and may have important toxicologic significance
regarding the mechanism of 1,2-dichloroethane toxicity.50
Introduction
The cellular tripeptide glutathione (GSH) can protect cells from both
endogenous and exogenous electrophiles that react with cellular constituents and cause
cell damage (Reed, 1985).It is now clear that glutathione conjugation can cause
cytotoxicity by enhancing the reactivity of a number of xenobiotic chemicals, such as,
some aliphatic halogenated alkenes (Dekant, et al., 1989), quinones (Mertens, et al.,
1991), and isothiocyanates (Ternmink, et al., 1986). The glutathione conjugate S-(2-
chloroethyl) glutathione (CEG), formed as a consequence of 1,2-dichloroethane (DCE)
conjugation with GSH, is another example of a toxification reaction. Although DCE
can be metabolized by an oxidative pathway via P450 2E1 leading to the reactive
metabolite 2-chloroacetaldehyde, it is believed that mutagenicity is due to the GSH-
conjugate pathway (Storer and Conolly, 1985). CEG can form an electrophilic
episulfonium ion that can react with specific nucleophilic sites in DNA (Humphreys, et
al., 1990; Ozawa and Guengerich, 1983). DCE metabolites also react with proteins
and DCE treated rats show signs of oxidative stress in the form of lipid peroxidation
(Sano and Tappel, 1990).
Covalent binding of reactive intermediates to proteins is accepted to be
important in the development of many chemical-induced toxicities, although the
detailed mechanisms by which these covalent interactions produce cellular toxicity are
not completely understood (Nelson and Pearson, 1990). Protein alkylation may cause
toxicity by (a) altering the protein such that loss of function occurs or by (b) creating
an immunogen that leads to a deleterious immune response (Hinson and Roberts,
1992).It is becoming clear that the amino acids alkylated in a protein are not
randomly targeted, but are determined by the nature of the electrophile (hard, soft),
available nucleophiles, and steric constraints imposed by the tertiary structure of the
protein. Protein adducts are often the focus of molecular dosimetry studies aimed at
quantifying exposure to carcinogens in the work place, such as measuring hemoglobin
adducts of ethylene oxide (Ehrenberg, et al., 1977; Osterman-Golkar, et al., 1976).51
Escherichia coli (E. coli) thioredoxin is a small, ubiquitous, redox-active
protein that has been studied extensively (Biguet, et al., 1994; Buchanan, et al., 1994;
Goto, et al., 1992; Oblong, et al., 1994). One of its many roles is as a hydrogen donor
for ribonucleotide reductase in the enzymatic synthesis of deoxyribonucleotides. Due
to its protein-disulfide reductase activity, the protective role of thioredoxin against the
effects of oxidative stress has been investigated. For example, thioredoxin has been
shown to enable lens epithelial cells exposed to hydrogen peroxide to recover from the
resulting oxidative damage, based on regeneration of G3PDH and leucine uptake
(Spector, et al., 1986). Recently, evidence has been obtained that the
thioredoxin/thioredoxin reductase system may regenerate enzymes inactivated by
oxidative stress in endothelial cells (Fernando, et al., 1992). Previous work in this
laboratory has shown that thioredoxin alkylated by CEG is inactivated, based on the
insulin reduction assay (Meyer, et al., 1994). The results of this assay strongly
implicate the active site as being targeted by CEG. Both eukaryote and prokaryote
thioredoxin contains a conserved active site having the sequence Trp-Cys-Gly-Pro-Cys,
which is present on a loop that protrudes from the three dimensional structure of the
enzyme (Holmgren, 1985). The purpose of this investigation was to study the
alkylation chemistry of CEG towards thioredoxin, and in particular, to identify which
amino acids become alkylated following reaction with the episulfonium ion of CEG in
vitro. To this end, we used a combination of peptide mapping and mass spectrometry
to determine CEG alkylation sites in thioredoxin.
Materials and Methods
Chemicals.Recombinant E. coli thioredoxin was purchased from
Calbiochem-NovaBiochem (La Jolla, CA). Reduced GSH, 4,4'-dithiopyridine (PDS),
and trifluoroacetic acid (TFA) were purchased from Sigma (St. Louis, MO). 1-bromo-
2-chloroethane (BCE) was purchased from Aldrich (Milwaukee, WI).
tris-(2-Carboxyethyl)phosphine (TCEP) was obtained from Pierce (Rockford, IL).52
Sequencing grade trypsin was from Boehringer-Mannheim (Indianapolis, IN). Labeled
GSH was synthesized from glutamic acid a-t-butyl ester, trityl-cysteine and "N-
glycine using a Wang resin (4-alkoxybenzyl alcohol polystyrene), all purchased from
Bachem (Torrance, CA). Bio-Gel P-2 gel (extra fine, <45 pm) with molecular weight
cutoff of 2000 Da was from Bio-Rad Laboratories (Richmond, CA). HPLC solvents
were purchased from J. T. Baker (Phillipsburg, NJ), and 18 megohm water was
prepared by a system (Waters, Bedford, MA ).
Synthetic procedures. CEG was synthesized according to the method of
Reed and Foureman (Reed and Foureman, 1986). CEG, purified by preparative
HPLC, contained at most 5% of the hydrolysis product as estimated by FAB/MS. The
alkylating ability of CEG towards thiols was assessed by a spectrophotometric
technique with PDS as described previously (Erve, et al., 1995). Some experiments
used CEG containing 50% 15N. CEG, consisting of 50 % N-labeled CEG, was
synthesized from a mixture of GSH containing 50% IN-Gly.'N-GSH was
synthesized manually, using standard Fmoc chemistry (Snyder, 1992). A Wang resin
was used as a solid support, and 'N-glycine was coupled to the resin according to the
procedures of Grandas et al. (Grandas, et al., 1988). The final product was purified
with preparative HPLC.
Reduction of thioredoxin by TCEP.Thioredoxin was reduced with a
phosphine derivative, TCEP. In a typical alkylation experiment, 300 lig (0.03 pmol)
of thioredoxin was reduced by addition of 25 lit of 8 mM TCEP (7 fold molar
excess) and incubated for 10 minutes to yield a 1.2 mM solution of reduced
thioredoxin. Disulfides are reduced by TCEP via a mechanism similar to that of the
trialkyl phosphines, which have been used to quantitatively reduce organic disulfides
(Fisher, 1993). The advantages of TCEP include its high solubility in water, activity
below neutral pH, selectivity towards disulfide bonds, and small molar excess needed
to quantitatively reduce disulfides (Bums, 1991).
Modification of Thioredoxin by the episulfonium ion of CEG.Aliquots of
reduced thioredoxin (50 tiL) were mixed with equal volumes of 0.4M ammonium
bicarbonate buffer (pH 7.7). CEG was weighed and dissolved in 40-70 111_, buffer and53
quickly added to the thioredoxin to give molar ratios ranging from equimolar to 25-
fold excess (CEG vs. thioredoxin). The pH dropped slightly with the addition of CEG
so that the pH of the reaction mixture was between 7.0 - 7.4. The reaction mixture
thus consisted of approximately 0.5 mM thioredoxin and from 0.5 to 12.5 mM CEG.
The reaction mixtures were incubated for 90 minutes at room temperature to insure
that the full alkylating capacity of CEG was utilized. The reaction mixture was then
injected onto an HPLC column and thioredoxin adducts were collected as described in
the instrumentation section.
Tryptic Digestion. The lyophilized CEG alkylated thioredoxin products (50 -
100 ttg) were dissolved in 0.4M NH4HCO3 buffer (pH 7.8) and reduced with SRL 8
mM TCEP. Free thiols were alkylated by adding 51,1L of 50 mM iodoacetamide (IAA)
and incubating at room temperature for 10 minutes. To denature the protein, 25 pi, 8
M urea was added. Sequencing grade trypsin was dissolved in 10 mM HC1 and 5 1.1,g
was added to the sample. The concentration of urea was reduced toabout 2M with
the addition of 45 1.tL H2O. Digestions were allowed to proceed for 18 hours at 37° C
before being stopped with the addition of 2 1.1L 50% TFA. Digests were either
analyzed immediately or stored at -80° C until analysis.
Bio-Gel separation of IAA from thioredoxin.Reduced thioredoxin was
alkylated at Cys-32 with IAA by reacting at pH 7.0. A spin gel column was prepared,
using a 1 mL pipette tip as a gel reservoir, that trapped IAA in the gel and allowed
thioredoxin to elute in the void volume (Chen, et al., 1992). The column was tested
for its ability to remove IAA by measuring the absorbance of IAA at 206 nm. A 50
!IL sample of 50 mM IAA showed no absorbance at 206 nm following filtration
through the spin-gel column. The thioredoxin/IAA sample was placed on top of the
spin-gel and spun at 2500 g for 6 minutes to remove unreacted IAA. The
carboxyamidomethylated-thioredoxin was recovered for latter use.
Instrumentation. Isolation of the CEG alkylated-thioredoxin products was
accomplished by reverse phase HPLC on an analytical C8 column (150 x 4.6 mm, 5
um, 30 angstroms, Vydac, Hesperia, CA). The elution gradient waslinear from 30%
B to 64% B in 20 minutes followed by an increase to 85% B over 5 minutes. The54
flow was 1 mL/tnin [solvent A = CH3CN/H20/11-A (5:95:1 v/v/v); solvent B =
CH3CNIIFA (100:0.8 v/v)]. Peptide mapping of the tryptic digests was accomplished
by reverse phase HPLC on an analytical C18 column (250 x 4.6 mm, 5 gm, 30 A,
Vydac, Hesperia, CA). The elution gradient was linear increasing from 5% B to 37%
B in 37 minutes, then to 70% B over 23 minutes and finally to 98% B in 12 minutes
with a flow of 1 mIimin [solvent A = CH3CN/H20/11A (5:95:1 v/v/v); solvent B =
CH3CN/H20/TFA (80:20:0.8 v/v/v)]. Mobile phases were prepared from HPLC grade
solvents and Nfilli-Q water and purged for 15 minutes with helium gas prior to use.
The liquid chromatography system included a Spectra Physics Series 8800 pump
(Freemont, CA), an Applied Biosystems 759 UV absorbance detector set for 215 nm,
an Hewlett-Packard (Palo Alto, CA) 3388A integrator/recorder, a dynamic mixer,and
a column heater to maintain a temperature of 29° C. Adducts and peptides were
collected manually and concentrated by spin-evaporation prior to further analysis.
Sequencing of the peptide (T3) that contained the allcylating moiety derived
from CEG was accomplished with a Perkin-Elmer Sciex API III plus triple-quadrupole
mass spectrometer (Sciex, Thornhill, Canada). The sample was introducedvia an
injector fitted with a 5 pt sample loop and infused into the mass spectrometer at a
rate of 1.2-2.5 4/min with a syringe pump (Harvard Apparatus, South Natick, MA)
and a solvent mixture of CH3OH/H20/formic acid (50:50:1 v/v/v). Collision induced
dissociation (CID) took place in the second quadrupole (RF only) with argon as a
collision gas at a density of 2.5 x 1014 molecules/cm2. The ion spray voltage was
5000 V, orifice voltage was 95 V, and collision energy 33eV (laboratory frame of
reference). Sequencing of peptide (T4) was at a collision energy of 25 eV, orifice
voltage of 45 V, and collision gas density of 3.4 x 1014 molecules/cm2.
MALDI mass spectrometry was accomplished with a custom built time-of-
flight instrument equipped with a frequency-tripled (355 nm) Nd:YAG laser (Spectra-
Physics GCR-11). The ion source was operated at 24 kV. Mass spectra were formed
by summing the data generated from 30 individual laser shots. Data analysis was
performed with m-over-z software provided by Dr. R C. Beavis at the Skirball
Institute, New York University Medical Center, NY. Lyophilized adducts or tryptic55
digests were redissolved in water. Typically, 1 1.1L of sample was mixed with 3-9 !IL
of matrix to obtain 1 to 10 .tM analyte concentration. For each analyses, 0.5-1 p,L
was deposited on the sample probe and air-dried at ambient temperature. The dried
sample was washed by dipping the probe tip into water and air-dried again. The
matrices used were either 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) or 4-
hydroxy-a-cyanocinnamic acid (HCCA).
FAB/MS was performed on a Kratos MS-50 double focusing instrument
operated at medium resolving power for raw data collection. A 2µL sample volume
was mixed on the tip of the sample probe with 2 !IL of matrix consisting of
thioglycerol/glycerol (2:1 v/v). Xenon gas was used to generate the primary ionizing
beam from an Ion-Tech gun operated at 7-8 kV.
Results
Alkylation of thioredoxin by the episulfonium ion derived from CEG. The reduced
form of thioredoxin has two cysteines at positions 32 and 35 that were expected to be
the major targets of the alkylating moiety derived from CEG (Figure 3.1). The
alkylated forms of thioredoxin were separated by reverse-phase HPLC
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Figure 3.1. E. coli thioredoxin protein sequence showing Cryptic peptides. The active
site containing the two cysteines is underlined. The asterisks denotes the alkylation
site on Cys-32 and the proposed alkylation site on Tyr-49.56
mainly on the basis of differences in polarity. The order of elution of the adducts is
tris-, bis, and mono-, although there was not much separation between the bis and tris
adducts. The alkylated forms of thioredoxin all elute prior to reduced thioredoxin;
oxidized thioredoxin had the greatest retention time and eluted last.Differences in the
distribution of the alkylated thioredoxins can be seen as the amount of CEG is
increased relative to thioredoxin. When adding 5-fold excess CEG over reduced
thioredoxin, there was approximately 20% mono adduct and no bis or tris adduct
(Figure 3.2). With 10-fold excess there was close to 50% mono adduct formed and a
small amount of bis adduct. With 25-fold excess CEG, reduced thioredoxin was
converted almost completely to adducted forms consisting primarily of the mono
adducted form and about 10% bis and tris adduct.
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Figure 3.2. HPLC analysis of reduced thioredoxin and its adducts. (A) 5-fold excess
CEG:thioredoxin, (B) 10-fold excess CEG:thioredoxin and (C) 25-fold excess
CEG:thioredoxin. Chromatograms represent the elution of 220 nm absorbing material
from the reverse phase column as described in Materials and Methods. TRX denotes
thioredoxin; MA, BA and TA denote mono-, bis- and tris- adducted thioredoxin,
respectively.57
Peptide mapping of Mono and Bis adducts.The mono adduct collected by HPLC
was rechromatographed before enzymatic digestion; as judged by MALDI mass
spectrometry the rechromatographed peak was very pure (Figure 3.3A). Following
typtic digestion, a portion of the digest was mass analyzed by MALDI. An intense
peak revealed at m/z of 2371 corresponds to the alkylated tryptic peptide T3
containing the adduct derived from CEG and one molecule of IAA from the digestion
procedure (Figure 3.4A). A portion of the peptide digest was chromatographed on a
C18 column. Comparing the resulting peptide map with that of untreated thioredoxin
allowed unknown peaks to be identified and collected (Figure 3.5A and 3.5B). As the
alkylated peptide was readily identified, not much effort was expended to determine
the identity of the remaining peaks in the peptide digest accounting for some unlabeled
peaks. Peaks that were identified are given in Table 3.1. For the mono adduct digest,
the peptide of interest had a retention time of approximately 44 minutes; this peptide
was collected and lyophilized prior to subsequent analysis.
Figure 3.3. MALDI/MS spectrum of (A) mono-alkylated reduced thioredoxin at m/z
12,004 and (B) bis-alkylated thioredoxin at m/z 12,340 following collection off the C8
HPLC column. The bis-alkylated thioredoxin spectrum shows the presence of a mono-
adduct as well as a tris-adduct.20
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Figure 3.4. MALDI/MS spectrum of the tryptic digests of (A) mono adduct and (B)
bis adduct. The digests were allowed to incubate at 37° C for 18 hours before being
analyzed.59
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Figure 3.5. Chromatographic separation of peptides produced following the Cryptic
digestion of (A) native thioredoxin and (B) thioredoxin mono-adduct.60
Table 3.1 Predicted and experimental masses of E coil thioredoxin treated with CEG
and digested with typsin.
Peptide Sequence Theoretical Observed
m/z m/z
Ti 1-3 349.2 n.d.
T11 97-100 445.3 n.d.
T7 70-73 508.3 508.0c
T5 53-57 531.4 531.4a
T10 91-96 574.4 574.4a
T9 83-90 789.4 790.4a
T12 101-018 892.4 892.4a
T8 74-82 1001.6 1001.6a
T6 58-69 1267.7 1267.6a
T11,12 97-108 1318.7 1318.5a
T2 4-18 1731.9 1731.8a
T8,9 74-90 1772.0 1772.8b
T4 37-52 1805.9 1806.0a
T4* 37-52 2140.0 2139.9a, 2139.2b,
2139.4c
T1,2 1-18 2062.0 2062.0a
T3A 19-36 2095.9 2095.0b
T3* 19-36 2370.9 2371.6a, 2371.0b,
2371.2c
* Peptide with adduct derived from CEG
A Cysteines are carboxyamidomethylated
a FAB/MS
b MALDI/MS
C Ionspray MS61
The bis-adduct of reduced thioredoxin was collected and rechromatographed prior to
digestion by trypsin. Although the HPLC peak appeared to represent a single
compound, MALDI mass analysis revealed additional compounds that could be
assigned to a mono-adduct and a tris-adduct (Figure 3.3B). The tryptic digest was
mass analyzed by MALDI prior to being chromatographed; the spectrum revealed an
intense peak at m/z 2,139 that could be assigned to the alkylated form of tryptic
peptide T4 (Figure 3.4B). This peptide appeared in the chromatographic peptide map
at 36 minutes and was well resolved from other known tryptic peptides; hence, it
could be collected off the HPLC system with relative ease.
Sequencing modified peptides by CID with Tandem mass spectrometry.
The peptide corresponding to T3 modified by the episulfonium ion of CEG produced
doubly (m/z 1,186.2) and triply (m/z 791.2) charged ions when analyzed by ionspray
mass spectrometry (Figure 3.6A). The doubly charged form of this peptide was
subjected to CID to produce a series of b and y fragment ions. CID spectra of
peptides are distinguished by a series of b and y fragment ions that provide sequence
information about the peptide (Biemann, 1988). By noting which peaks in the CID
spectra shifted compared to the expected fragments for an unalkylated peptide, it was
possible to identify the amino acid which had undergone alkylation by CEG. The CID
spectrum of alkylated T3 produced y3 through y14 and b2 through b9 fragment ions
(Figure 3.6B). The y5y14 ions were shifted 334 amu above their expected mass
values in the unalkylated peptide, whereas y3 and y4 were only shifted by 58 amu, the
mass increment associated with alkylation by IAA. In addition, y5 lost a glutamic
acid residue from the adduct derived from CEG to produce the observed ion at m/z
768. These observations are consistent with an adduct derived from CEG on Cys-32
and a carboxyamidomethyl moiety on Cys-35. No fragment ions could be identified
that would indicate alkylation by CEG's episulfonium ion at Cys-35.
The peptide, which produced a MALDI signal at m/z 2,139 displayed a doubly
charged ion at m/z 1,070 and a triply charged ion at m/z 714 in the ionspray mass
spectrum. The triply charged ion was subject to CID because the doubly charged ion
was too weak for tandem MS analysis. The product ion spectrum produced was not as62
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Figure 3.6.(A) Ion-spraymass spectrum of alkylated T3 showing doubly and triply
charged species. This peptide was collected from the tryptic digest of the mono-
adduct. (B) Spectrum of daughter ions formed by CID of the[M+2H]+2parent (m/z
1,186) of the allcylated peptide T3, obtained byionspray MS/MSon a Sciex API III
triple quadrupole mass spectrometer by direct infusion of the sample into the ion
source. The ion denoted by an asterisks corresponds to Cys32-Gly-Pro-Cys35-Lys
alkylated by CEG at Cys32 and by IAA at Cys35. This ion loses a glutamic acid
residue from the adduct derived from CEG to produce the ion signal at m/z 768.63
informative as that obtained for alkylated T3. Fragment ions were formed, but no ions
shifted by the mass of the alkylating species could be identified among the ions
detected. An ion signal observed at m/z 334 is consistent with extensive loss of the
alkylating species ion from the peptide during the CID process; this could account for
our inability to ascertain the site of alkylation on this peptide by thismethod.
Alkylation with 'N-labeled CEG. This work and previous work produced
evidence that tris- as well as tetra- adducts of thioredoxin were present (Meyer, et al.,
1994), albeit, in low amounts. The tetra-alkylated thioredoxin was formed with a
much larger excess of CEG than used in the experiments described in the present
work. In an attempt to identify these sites of alkylation, oxidized thioredoxin was
alkylated with a mixture of CEG that contained 50% '5N labeled glycine with the
expectation that the isotopic pattern of the alkylated peptides would point to possible
alkylation sites. Oxidized thioredoxin, which has no free thiols, was used to assure
that alkylation could not occur at the cysteines. The reaction products of oxidized
thioredoxin alkylated with 35-fold excess CEG were chromatographed by HPLC; the
resulting chromatogram showed an adduct peak representing 11% of oxidized
thioredoxin and two smaller adduct peaks that account for 2.2% and 1.4% of the area
of oxidized thioredoxin, respectively. The largest chromatographic adduct peak
consisted primarily of bis-adduct but contained a small contribution from tris-adducted
thioredoxin as shown by ionspray mass analysis (data not shown). The mass analysis
of the minor chromatographic peaks also showed evidence of coelution of bis- and
mono-adducts. Another reaction was carried out with the aim of producing sufficient
bis-adduct to allow for peptide mapping of a tryptic digest. Reaction of 300 fold
excess CEG over oxidized thioredoxin increased the amount ofbis-adduct so that its
area now accounted for approximately 45% of that of the unreactedoxidized
thioredoxin when chromatographed by HPLC. Mass analysis of the tryptic digest by
MALDI showed the presence of alkylated tryptic peptide designated as T4. This
peptide was examined at medium resolution by FAB mass spectrometry. The isotopic
pattern observed for this peptide matched the theoretically predicted pattern (Figure
3.7), and, thus, gave additional support for this peptide indeed being alkylated by the64
episulfonium ion of CEG. No other alkylated peptides were observed, possibly
because sensitivity for the CEG-allcylated peptides was not very high in FAB/MS. It
maybe that CEG adducted peptides at amino acids other than cysteineare not stable
and lose the alkylating moiety during the digestion and/or peptide mapping.
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Figure 3.7. Medium resolution FAB mass spectrum of the isotopic pattern of T4 with
m/z 2,141 obtained from a tryptic digest of an oxidized thioredoxin adduct alkylated
with a 50% mixture of 15N-labeled CEG. Below is the isotopic pattern of the peptide
with the expected elemental composition that should be observed, assuming allcylation
by the episulfonium ion of CEG.
Reaction of Reduced Thioredoxin at high pit In order to investigate the reactivity
of Cys-35 towards the episulfonium ion of CEG, reduced thioredoxin was first treated
with IAA at pH 7.0. Only Cys-32 is present as the thiolate anion and will react with
IAA (Kallis and Holmgren, 1980). Unreacted IAA was removed using a P-2 gel.
Mass analysis of the resulting product by MALDI revealed a peak at m/z 11,728 that65
would correspond to the expected thioredoxin with carboxyamido-methylationat Cys-
32 with no alkylation at Cys-35. CEG was then added in excess after the pH had
been adjusted to 8.5. The higher pH would result in at least 65% of the Cys-35 thiol
ionized, assuming a plc of 7.9 (Huimin, et al., 1993). Following this reaction, and
addition of more IAA, HPLC showed the formation ofone major product (Figure 3.8).
A MALDI peak for this thioredoxin product was observed at m/z of 11,786, which
corresponds to thioredoxin with two molecules of IAA but no adduct derived from
CEG.
Discussion
The results of this study confirm prior findings that the episulfonium ion of CEG isa
chemically reactive species capable of alkylating nucleophilic sites in the protein
thioredoxin at physiologic pH The focus of the present investigationwas to identify
the specific amino acids that undergo alkylation when adducts are formed between the
episulfonium ion of CEG and thioredoxin. Reaction of reduced thioredoxin resulted in
the formation of at least three adducts the major of which is a mono-adduct that
readily forms with only a 10-fold molar excess of CEG over thioredoxin. Themono-
adduct was digested with trypsin, and the peptide containing the alkylating moietywas
sequenced by tandem mass spectrometry. The sequencing analysis showed the site of
alkylation to be exclusively at Cys-32, which is one of the two active site cysteines.
The preference for this alkylation site was anticipated because Cys-32 hasa lower pKa
than Cys-35. The pKa values of Cys-32 and Cys-35 have been measured by Raman
spectroscopy to be 7.1±0.2 and 7.9±0.2 (Huimin, et al., 1993). The y5 ion present in
the cup spectrum (Figure 3.6B) contains the alkylating moiety and also fragments by
loss of a glutamic acid residue from the adduct derived from CEG. A similar
observation was observed for the adducts of oxytocin alkylated by CEG at its two
cysteines (Erve, Deinzer and Reed, 1995). Cys-35's lack of reactivity at pH 8.5 was
unexpected because at this pH it is presumed to be at least 65% ionized. TheThioredoxin + IAA (pH 7)
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Figure 3.8. HPLC chromatogram of thioredoxin treated with IAA and CEG at pH 8.5.
Major peak represents thioredoxin with two adducts of IAA.67
alkylating agent IAA, which is smaller relative to CEG, is able to alkylate Cys-35at
this pH ((Ka llis and Holmgren, 1980), and this study). The active site of reduced
thioredoxin has been determined by NMR (Dyson, et al., 1990) and is lcnownto have
the cysteines on a protruding loop with Cys-32 exposed. In comparison, however,
Cys-35 is not as exposed (Eklund, et al., 1991). Given that tertiary structure is
important in directing alkylation towards specific nucleophiles andaway from others,
it is possible that the relatively large episulfonium ion of CEG cannotaccess Cys-35.
A bis-adduct of reduced thioredoxin produced a peptide digest that contained
alkylated T3 and T4 tryptic peptides. As for the mono- adduct, this adductwas also
alkylated at Cys-32. Attempts to determine the site of alkylation in the peptide T4 by
tandem mass spectrometry failed, ostensibly because the adduct derived from CEG
fragmented during CID. The most likely amino acid in this peptide to undergo
alkylation by the episulfonium ion of CEG on this peptide is Tyr-49, because after
thiol groups the hydroxyl functional group on tyrosine is the next most reactive
nucleophile towards the alkylating species derived from CEG (Jean and Reed, 1989).
Tyrosine in the peptide angiotensin was shown to be alkylated following treatment
with styrene oxide (Ferranti, et al., 1992). A molecular model of thioredoxin shows
that Tyr-49 is on the surface of the protein, further supporting the plausibility of this
target. Tyrosine in the peptide oxytocin was also suspected of being alkylated by the
episulfonium ion of CEG; however, this could not be confirmed because the complete
adduct fragmented off the peptide (Erve, Deinzer and Reed, 1995). Regardless of
where the bond is formed in this second alkylation of thioredoxin, it is definitelymore
labile under CID conditions (with the collision parameters used) than is the sulfur-
adduct bond. The significance of this putative allcylated Tyr-49 on thioredoxin is not
known. The iris adduct, being formed in much smaller amounts, could be neither
purified nor digested so that the third site of alkylation could not be identified.
When oxidized thioredoxin was alkylated by the episulfonium ion of CEG and
then chromatographed, several smaller adduct peaks eluted before oxidized
thioredoxin. These adducts were formed in much smaller amount than the major
mono-adduct formed with reduced thioredoxin, indicating that nucleophilic sites other68
than the cysteine thiol are much less reactive towards CEG's episulfonium ion.
MALDI mass analysis shows that the largest chromatographic peak is actually the
result of two coeluting peaks. The tryptic digest was mass analyzed by MALDI and
an allcylated T4 was identified. There is not much difference between the tertiary
structure of reduced and oxidized thioredoxin (Dyson, et al., 1990), and it is probable,
therefore, that this T4 peptide adduct of oxidized thioredoxin is alkylated at thesame
site (putatively at Tyr-49) as that on reduced thioredoxin. Wewere not able to
identify other alkylated peptides in the tryptic digests of these adducts by either FAB
or MALDI mass spectrometry.It is possible that the adduct formed is unstable and is
cleaved off the amino acid during proteolytic digestion. This possibility is supported
by our attempt to further digest the T4 peptide adduct with endoproteinase Glu-C. A
12 hour incubation of the peptide with enzyme at 50° C producedno observable
digestion of the peptide but it did result in loss of the adduct derived from CEG. That
is, we no longer observed alkylated T4 but instead only unalkylated T4, suggesting
that the adduct was unstable at this incubation temperature.
Protein alkylation is known to play a role in the mechanism of toxicity ofa
number of drugs, such as, acetaminophen (Mitchell, et al., 1973) and xenobiotics, such
as, bromobenzene (Jollow, et al., 1974).It is possible, however, that a given protein
adduct has no toxicologic consequence and therefore, it is not sufficient to simply
show that a protein has been adducted to infer a toxicologic mechanism. For example,
alkylation of alcohol dehydrogenase by the active metabolite of N, N-dimethy1-4-
aminoazobenzene causes only minor alterations in enzyme activity and has been
regarded as a detoxification pathway for this compound (Coles, et al., 1987).
Therefore, the capability to identify the particular amino acid that has undergone
alkylation by CEG's episulfonium ion in a protein might point to a toxicological role
for protein alkylation as a mechanism of toxicity, especially if the amino acid is vital
to the functioning of the protein. In this work, we have used a combination of
MALDI and ionspray tandem mass spectrometry to show that one of the active site
cysteines of the enzyme thioredoxin, Cys-32, is alkylated by CEG's episulfonium ion
at physiologic pH. This finding supports previous work in this laboratory that showed69
the partial loss of thioredoxin insulin reduction activity following in vitrotreatment
with CEG (Meyer, et al., 1994). Such loss of activitysuggests that if levels of CEG
in target cells were high enough an importantenzyme required for a number of
functions in vivo might be inactivated.
To ascertain the consequences of our findings,an antibody against CEG-
allcylated thioredoxin would aid in determining if thioredoxin is alkylated inisolated
hepatocytes or in vivo following the administration ofa toxic dose of DCE.
Demonstration of alkylated thioredoxin as a critical target in vivo would strengthenthe
implication that CEG plays a role in the toxicity of DCE. Microsomal metabolitesof
DCE are known to be reactive towards protein,eg. lung microsomal proteins
(Banerjee, et al., 1980). Hence, it would be useful tocompare the reactivity of 2-
chloroacetaldehyde, a P450 metabolite of DCE, towards thioredoxin in orderto better
understand the relative importance of the GSH-conjugation pathway and the
microsomal oxidation pathway in the toxicity of DCE. It would also be of interestto
investigate the fate of thioredoxin alkylated by CEG in cells.Is it possible, for
instance, that alkylated thioredoxin will be degradedmore quickly than unalkylated
thioredoxin? Eventually, it will be important to know whether human thioredoxin is
alkylated by the episulfonium ion of CEG, becauseexposure to DCE occurs for certain
workers (Williams and Diwan, 1994).70
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Chapter V
Determination of Hemoglobin Sulfhydryl Status Following Alkylation
by S-(2-chloroethyl)glutathione with Mass Spectrometry and
Spectrophotometry
John C. L. Ewe
Max L. Deinzer
Donald J. Reed72
Abstract
Human hemoglobin was alkylated at physiologic pH by the episulfonium ion of
S-(2-chloroethyl)glutathione (CEG) in order to investigate if hemoglobin might serve
as a biomarker of exposure for 1,2-dichloroethane encountered in the workplace. In
vitro alkylation resulted in three alkylation products on the a chain and at least two
alkylation products on the 1chain as determined by MALDI mass spectrometry. To
determine if the site of alkylation was the reactive sulfhydryl present at Cys-93 on the
13 chain of hemoglobin, a spectrophotometric assay using 4,4'-dithiopyridine was used
to measure the free sulfhydryl groups before and after treatment with various amounts
of CEG. Results indicate that the episulfonium ion of CEG did not react at the
sulfhydryl group, as there was no decrease in the sulfhydryl to hemoglobin ratio, even
at very high ratios of CEG to hemoglobin. In contrast, iodoacetamide did react with
the sulfhydryl groups and gave a dose dependent decrease in the sulfhydryl to
hemoglobin ratio as measured by this assay. CEG treated hemoglobin was digested
with Staphlycoccus aureus endoproteinase Glu-C and the digest analyzed by FAB
mass spectrometry. Efforts to identify specific alkylated peptides on hemoglobin were
unsuccessful due to the difficulty in isolating a pure adducted protein prior to
digestion. These results indicate that although the episulfonium ion of CEG does
alkylate human hemoglobin, the levels required are much higher than what would be
expected in vivo and do not encourage further study with respect to biomonitoring
based on measuring hemoglobin adducts.73
Introduction
Hemoglobin, an oxygen transport protein, is found in erythrocytes and carries
oxygen from the lungs to tissues throughout the body. It is a tetramer with a
molecular weight of 64,450 Da, and is composed of two dimers each consisting of two
distinct polypeptide chains (Dickerson and Geis, 1983). In the fields of toxicology
and molecular epidemiology, hemoglobin has been used as a biomarker for chemical
exposure in the work place to measure the amounts of carcinogens in the body such as
ethylene oxide (Farmer, et al., 1986), propylene oxide (Osterman-Golkar, et al., 1984),
acrylamide (Bergmark, et al., 1993), and acrylonitrile (Osterman-Golkar, et al., 1994).
Biomonitoring has also been used to quantify the adducts of the chemotherapeutic
agent 1-(2-chloroethyl)-1-nitrosourea in cancer patients receiving this drug in order to
monitor therapy (Bailey, et al., 1991). The purpose of hemoglobin biomonitoring is
ultimately to determine whether an individual has suffered genetic damage and to
estimate the possible risk of cancer from this carcinogen; the amount of hemoglobin
adduction in the exposed individual is important in arriving at these conclusions
(Calleman, et al., 1978; Ehrenberg, et al., 1974). Biomonitoring relies on a variety of
nucleophilic sites in hemoglobin which can combine with reactive electrophilic
metabolites. The amino acidscysteine, histidine, lysine, aspartic acid and N-terminal
valinereact specifically with a number of chemicals. Hemoglobin is easily sampled
and, because the erythrocyte has a life-time of 120 days, it integrates a person's
cumulative exposure to the carcinogen over that time (van Welie, et al., 1992). Many
analytical techniques have been developed to quantify hemoglobin adducts of certain
chemicals. Examples include a modification of Edman degradation which has been
applied to N-terminal valine adducts of ethylene oxide (Tomquist, et al., 1986), mild
basic hydrolysis followed by derivati7ntion with pentafluoropropionamide and GC/MS
analysis for 4-aminobiphenyl adducts on cysteine (Bryant, et al., 1987), and Raney
nickel to cleave the bond between cysteine and styrene oxide (Ting, et al., 1990).74
The compound DCE is subject to both microsomal metabolism mediated by
cytochrome P450 enzymes and glutathione conjugation mediated by cytosolic GST
activity (Storer and Conolly, 1985). The product of the latter pathway is CEG, which
can form an episulfonium ion by the intramolecular displacement of chlorine by sulfur.
The episulfonium ion of CEG can alkylate nucleophilic sites on DNA which have been
identified primarily at the N7 of guanine (Humphreys, et al., 1990). This is thought
responsible for the mutagenicity and carcinogenicity of DCE (Storer and Conolly,
1985).It has been shown that the episulfonium ion of CEG reacts readily with the
sulfhydryl group of cysteine, and to a lesser extent, the hydroxyl group of tyrosine
residues in the peptide oxytocin (Erve, et al., 1995b) and the protein E coli
thioredoxin (Erve, et al., 1995a; Meyer, et al., 1994). CEG formed in vivo can be
detected in the bile of rats dosed with BCE (Marchand and Reed, 1989) and can cause
renal proximal tubular damage in rats (Kramer, et al., 1987).
In erythrocytes, hemoglobin is the predominant protein representing90% of
the total cytosolic protein. Erythrocytes also contain reduced GSH in millimolar
concentrations, which has been shown to be important for maintaining sulfhydryls in
the reduced state and detoxifying trace amounts of hydrogen peroxide (Srivastava and
Beutler, 1970). GST enzymes have been identified in human erythrocytes that are
capable of metabolizing a number of small molecular weight halogenated
hydrocarbons such as methylbromide, methylchloride and methyliodide (Hallier, et al.,
1990).It appears that a polymorphism exists with respect to this activity with 75% of
the population thought to be conjugators and the remaining 25% non-conjugators
(Hallier, et al., 1993). We decided to investigate the ability of the episulfonium ion of
CEG to alkylate human hemoglobin in vitro since this is requisite if hemoglobin were
to serve as a biomarker of human exposure to DCE. GSH protects hemoglobin from
alkylation by IAA, signifying that GSH lowers the sensitivity of hemoglobin
biomonitoring towards electrophilic agents that can be detoxified by GSH (Evelo and
Henderson, 1988). In the case of DCE, GSH is used in the process of forming the
reactive conjugate, possibly diminishing its protective role. The purpose of the present
investigation was to determine if the episulfonium ion of CEG forms adducts on75
hemoglobin at physiologic pH, and if the site of adduction is the highly nucleophilic
13-93 cysteine sulfhydryl. To this end, we used reverse-phase HPLC to chromatograph
reaction mixtures resulting from the treatment of a hemolysate with CEG, and MALDI
mass spectrometry to measure the masses of the individual a and 13 chains of
hemoglobin. The f3-93 cysteine was monitored with a spectrophotometric assay
utilizing PDS.
Materials and Methods
Chemicals. Lyophilized human methemoglobin standard, Drabkin's solution
(20 parts K3Fe(CN)6, 100 parts sodium bicarbonate, 5 parts KCN),TFA, PDS and
IAA were obtained from Sigma (St. Louis, MO). Endoproteinase Glu-C from
Staphlycoccus aueus, also known as V8, was purchased from Boehringer Mannheim
(Mannheim, Germany). Human blood was obtained from the first author by
venepuncture and collected into a 5 mL EDTA containing Vacutainer tubes from
Beckton Dickinson. HPLC solvents were purchased from J. T. Baker (Phillipsburg,
NJ) and 18 megohm water was prepared by a Milli -Q system (Waters, Bedford, MA).
Dialysis tubing (1.4 cm width) with a molecular weight cut-off of 6 to 8 kDa was
from Spectra/Por (Spectrum, Houston, TX)
Synthetic procedures. CEG was synthesized, according to the method of
Reed and Foureman (Reed and Foureman, 1986), in a three-necked round-bottomed
flask starting with 0.5 g GSH. 50 ml of liquid ammonia was obtained by condensing
gaseous anhydrous ammonia with an ice-bath of ethanol and dry ice. At a temperature
of approximately - 40°C, pellets of metallic sodium were added until there was a
permanent blue color; this usually required 4-6 pellets. Approximately 0.80 mL of
BCE was added dropwise via a 1 mL glass syringe. With the addition of BCE the
reaction mixture would turn white. The reaction was maintained at -40° for 45
minutes after which the ammonia was evaporated. The crude CEG was lyophilized at
least 12 hours before further purification by preparative HPLC (Figure 4.1A).76
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Figure 4.1. FAB mass spectrum of (A) crude CEG preparation showing CEG present
as sodium adducts and (B) purified CEG. The purified CEG is visible at m/z 370; the
small peak at m/z 352 represents the hydrolysis product, HEG.
Hemolysate Preparation. Hemolysate was prepared according to the procedure of
Attoni and Brunori (Antonini and Brunori, 1971). Briefly, approximately 4 mL of
whole blood was centrifuged at 200 x G to separate red blood cells (RBCs) from
plasma. The RBCs were washed three times with cold isotonic saline. To lyse the
RBCs, a volume of cold water three times the volume of the RBCs was added and
allowed to stand 30 minutes at 4°C. Membrane proteins were precipitated by adding
one volume saturated ammonium sulfate for every four volumes of hemolysate and
allowing to stand for 45 minutes. The lysate was then centrifuged at 10,000 x G for
30 minutes on a Sorvall centrifuge (4°C) after which the clear supernatant77
(hemolysate) was transferred to dialysis tubing. The hemolysate was dialyzed against
three changes of 0.05 M phosphate buffer, pH 7.4 for 36 hours. The hemolysate was
stored at 4°C and used within two weeks.
Instrumentation. Preparative HPLC purification of crude CEG was achieved
with a C18 reverse phase column (22mm x 28 cm, Whatman). Crude CEG elution
was accomplished with an isocratic solvent containing methanol/H20/glacial acetic
acid (9:91:4 v/v/v) at a flow of 10 mL/min. The liquid chromatography system
included twin model 110 Altex pumps and a fixed wavelength UV detector (LKB-
Produkter AB, Broma, Sweden) set at 220 nm and a 750 laL sample injection loop.
Chromatograms were recorded with an Spectra-Physics (SP4200) computing integrator.
Between 40 and 50 mg crude CEG was dissolved in 650 µL 0.2% acetic acid and
immediately injected onto the column. The CEG, which eluted in 35-40 minutes, was
collected in a lyophilization jar partially submersed in liquid nitrogen. At the end of
the day, the frozen mixture of CEG was lyophilized to remove the solvent. The final
purified CEG contained at most 5% impurity of the hydrolysis product, HEG, as
estimated by FAB mass spectrometry (Figure 4.1B).Up to 400 mg of crude
preparation could be purified per day (Figure 4.2).
9% Me0H/H20 isocratic;
flow = 9 mUmin
HEG
CEG
10Minutes20 30
Figure 4.2. Preparative HPLC chromatogram recorded during purification of CEG.78
Hemoglobin was chromatographed on a C4 analytical HPLC column (250 x 4.6
mm, 30 angstroms, Custom LC, Houston, TX). The elution gradient was linear from
42% B to 85% B over 45 minutes with a flow of 1 mL/min [Solvent A=
CH3CN/H20/114A (20/80/1 v:v:v); solvent B = CH3CN/H20/11-A (80:20:0.8 v/v/v)].
The liquid chromatography system consisted of a Spectraseries P200 HPLC pump
(Spectra Physics, Freemont, CA), a variable wavelength UV absorbance detector set
for 220 nm (Spectraflow 757) and an integrator (Hewlett Packard, Palo Alto, CA).
Hemoglobin a and 13 chains and their adducts were collected manually and
concentrated by roto-evaporation prior to mass spectrometric analysis.
Matrix-assisted laser desorption-ionization (MALDI) mass spectrometry was
accomplished with a custom built time-of-flight instrument equipped with a frequency-
tripled (355 nm) Nd:YAG laser (Spectra-Physics GCR-11). Sample preparation and
data analysis were described elsewhere (Erve, et al., 1995a). Ionspray mass
spectrometry was accomplished with a Sciex III plus triple-quadrupole mass
spectrometer (Sciex, Thomhill, Canada); conditions were as described elsewhere (Erve,
Deinzer and Reed, 1995b). Fast atom bombardment (FAB) mass spectrometry was
performed on a Kratos MS-50 double focusing instrument operated at a resolution of
1000 for raw data collection. A 2 [IL sample volume was mixed on the probe tip with
2 'IL of matrix consisting of thioglycerol/glycerol (2:1 v/v). Xenon gas was used to
generate the primary ionizing beam from an Ion-Tech ion gun operated at 7-8 kV.
Spectrophotometric measurements was performed on either a SLM AMINCO
DW2000 UV-vis spectrophotometer (Milton Roy, Rochester, New York) or a Uvikon
810 UV-vis spectrophotometer. Quartz cuvettes (1 mL for hemoglobin standards; 3
mL for sulfthydiy1 determinations) were used in all measurements. The instrument was
zeroed with a phosphate buffer blank.
Hemoglobin Concentration Measurements. Hemolysate hemoglobin
concentrations were determined by Drabkin's method as modified by van Kampen and
Zijlstra (van Kampen and Zijlstra, 1983). Hemoglobin standards were prepared by
dissolving lyophilized cyanomethemoglobin in Drabkin's reagent to give the following
concentrations: 0, 20, 40, 60, 120 and 180 mg/mL. Each standard was measured in0.5
0.4 -
0.3
0.2 -
79
triplicate at 540 nm to create a calibration line (Figure 4.3). A 10 !IL sample of
hemolysate was diluted with 1 mL of Drabkin's reagent and measured in triplicate.
The resulting absorbance was used to calculate the hemolysate hemoglobin
concentration from the calibration line or with the molar extinction coefficient of
0.1-
0
Dw2000
o Uvikon
y = 0.003x + 0.000r2 = 1.000
£ =43,684 M- 'cm-1
0 40 120 160
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Figure 4.3. Calibration lines for cyanomethemoglobin standards at 540 nm.
cyanomethemoglobin, 44,000 M' cm -1 (van Kampen and Zijlstra, 1983). After
determining the concentration of the hemolysate, it was diluted with phosphate buffer,
pH 7.4 to approximately 2-4 x 104 M for use in experiments. Buffer concentration
was approximately 200 mM phosphate. In order that hemoglobin concentrations could
be determined by absorbance at 324 nm, some hemolysate was carefully diluted to
make a set of standards of known concentration. These were used to construct a
calibration curve based on absorbance at 324 nm, which gave a molar extinction80
coefficient of 71,562 M1 cm -1 (Figure 4.4A); Neis and coworkers reported a value
of 80,600 M-1 cm -1 (Neis, et al., 1984).
Hemoglobin alkylation by IAA or the episulfonium ion of CEG.
Hemolysate was reacted with equimolar, 2, 5, 10 and 20 fold excess IAA over
hemoglobin. CEG was added in 100, 250 and 500 fold excess over hemoglobin.
Both mixtures were allowed to react at room temperature; IAA was allowed to react
for 30 minutes while CEG was allowed to react for 90 minutes. For some
experiments, the hemoglobin CEG reaction mixtures were injected onto a C4 column
so that a and 13 chains and their adducts could be collected for MALDI mass
spectrometry analysis. For other experiments, the reaction mixtures were analyzed for
protein sulfhydryl content as described below.
Hemoglobin sulfhydryl determination. To determine sulfhydryl
concentrations following reaction with either IAA or CEG, 100 1.LL of the
corresponding reaction mixture was diluted to 10 mL with 0.05 M phosphate buffer
(pH 7.4). This was divided into three 2.90 mL aliquots. To one aliquot, 100 IlL of
water were added and hemoglobin concentration calculated based on its absorbance at
324 nrn. To the other two aliquots, 100 [t.L, of 1 mM PDS were added. A PDS blank
was also prepared. The vials were stoppered and incubated in the dark for 40 minutes
at 37° C. After incubation, the vials were allowed to reach room temperature before
measuring the absorbance at 324 nm. Sulfhydryl concentrations were determined by
dividing the absorbance by the molar extinction coefficient for PDS, determined by
cysteine titration to be 20,117 M-1 cm -1 (Figure 4.4B). Reported values of the molar
extinction of PDS were 19,800 M-1 cm -1 (Grassetti and Murray, 1967) and 20,500 M
1 cm -1 (Neis, et al., 1984). Ratios of hemoglobin sulfhydryl concentration to
hemoglobin concentration were calculated by dividing the appropriate values.
Enzymatic digestion of hemoglobin. Hemoglobin, both native and CEG-
treated, were digested with Endoproteinase Glu-C (also known as V8). Approximately
1500 pmole hemoglobin was dissolved in 50 1.1.L 50 mM ammonium bicarbonate (pH
7.8). 20 [tL 8M urea was diluted to about 2M with water to denature the protein.81
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Figure 4.4. Measurement of the molar extinction coefficient (e) at 324 nm for (A)
PDS and (B) hemoglobin. The 3 calibration lines in (A) were obtained by titration
with 2 mM cysteine and averaged to give the calculated value. The line in (B) was
obtained by diluting a known concentration of hemolysate and measuring absorbance
of hemoglobin at 324 nm.82
Enzyme was added in a ratio of 1:10 (enzyme:protein) and the digest was allowed to
incubate 4-6 hours at 37°C. The digestion was terminated by adding 5 1.1L of 50%
TFA before analyzing by FAB mass spectrometry.
Results
Human hemoglobin reacted with CEG in vitro at pH 7.4 resulted in the
formation of a number of adducts as determined by both ionspray and MALDI mass
spectrometry. With acetonitrile as a solvent, hemoglobin denatures when
chromatographed, resulting in the separation of heme from the two polypeptide chains.
Under these conditions, heme elutes first as a sharp peak followed by the 13 chain and
a chain. However, when hemoglobin treated with CEG waschromatographed, no
distinct adduct peaks appeared as was observed for the adducts of oxytocin (Erve,
Deinzer and Reed, 1995b) or the adducts of thioredoxin (Erve, et al., 1995a).Rather,
the peaks representing the a and 13 chains became less sharply defined. The 13 chain
appeared to become broader at a lower level of CEG compared to the a chain (Figure
4.5). At the highest level of CEG, both chains chromatographed as very broad peaks.
Other efforts to achieve separation between native and alkylated hemoglobin included
using RP-HPLC chromatography with a C8 column, and a combination of cation-
exchange chromatography followed by RP-HPLC chromatography with a C4 column;
both attempts were without success.
When these peaks were analyzed by MALDI mass spectrometry it was apparent
that both chains of hemoglobin had undergone alkylation by the episulfonium ion of
CEG. In particular, mass spectral evidence supported the assignment of three adducts
on the a chain and two on the 13 chain (Figure 4.6Aand 4.6B). Ionspray mass
spectrometry also produced evidence of adducts derived from CEG on both chains
(data not shown).Hb 13 Hb a \ ...-----
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Figure 4.5. HPLC chromatograms of hemoglobin treated with increasing amounts of
CEG. The heme elutes first followed by the 13 chain and a chain. The chromatogram
represents the elution of UV absorbing material at 220 nm.3
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Figure 4.6. MALDI mass spectrum of (A) a-chain and three adducts and (B) 13-chain
and two adducts. The adducts were collected manually from the HPLC and roto-
evaporated to dryness prior to analysis. The adducts were dissolved in water and
mixed with sinnapinic acid as a matrix.85
The hemoglobin reaction mixtures were also analyzed to determine the extent of
reaction of either IAA or CEG with the two sulfhydryl groups in hemoglobin. A
similar experimental design has been used to monitor the disappearance of free
sulfhydryl groups after exposure to a number of different alkylating agents in vitro
(Neis, et al., 1984). Following the reaction between IAA and hemoglobin, there was
a clear dose dependent decrease in sulfhydryl concentration with increasing amounts of
IAA (Figure 4.7, insert). With 2-fold excess IAA to hemoglobin, the sulfhydryl
concentration had decreased to 75% of the control. At the highest dose, 20-fold
excess, the sulfhydryl concentration was only 7% of the control indicating extensive
modification of the two reactive sulfhydryl groups. After reaction with CEG,
however, no such decrease was observed even at 500-fold excess CEG to hemoglobin
0 100 200 300 400
Molar Excess CEG over Hemoglobint
15.68 x 10 8 moles
600
Figure 4.7. The ratio of sulfhydryl to hemoglobin concentration following treatment
with 100X, 250X and 500X fold excess CEG. Measurements were made
spectrophotometrically with PDS. Insert A show the ratio of sulfhydryl to hemoglobin
concentration following treatment with up to 20 fold excess IAA.86
(Figure 4.7). That CEG did react with sulfhydryl groups was demonstrated by
reaction with GSH. Reacting 5-fold excess CEG over GSH reduced the free
sulfhydryl concentration by over 90% as determined by the decrease in PDS
absorbance. On examination of an absorption spectrum between 200 and 550 nm of
hemoglobin present in the reaction mixtures, however, it was clear there were changes
for CEG treated hemoglobin when compared to native hemoglobin.In particular,
there was both a hypsochromic shift (shift to lower X) and decrease in intensity of the
Soret band observed for the hemoglobin samples treated with 250- and 500-fold excess
CEG (Figure 4.8). In the case of the 500-fold CEG treated sample, there was also a
change around 280 nm corresponding to the region of tyrosine absorption. For
hemoglobin treated with the same excess IAA (100, 250, 500) there was neither a
hypsochromic shift nor decrease in the intensity of the Soret band. There were
changes in the tyrosine absorption region (data not shown).
Enzymatic digestion by V8 of both native PI chain, and a peak containing
predominantly CEG-alkylatecl hemoglobin 3 chain produced a number of expected
peptide fragments (Table 4.1). The treated sample contained many of the same
Table 4.1 Calculated and observed V8 digest fragments of CEG alkylated hemoglobin
by FAB mass spectrometry.
Fragment Sequence Theoretical m/z Observed m/z
V1 1-6 695.4 695.5
V1,2 1-7 824.4 824.5
V7 91-101 1305.6 1305.7
V3 8-22 1616.9 1616.9
V5 27-43 2095.2 2096.1
V8 102-121 2266.2 2267.1
V1,2,3 1-22 2427.2 n.d.
V9 122-146 2680.4 2681.6
V6 44-90 4843.5 4843.2
V7* 91-101 1639.7 1638.7
*The mass of this peptide could correspond to the addition of
derived from CEG to V7, ie. V7 + 334 Da.
the alkylating moietyhemoglobin treated with CEG7
02: 47: 34a 10-03-1992#16
SPLIT BEAM
SLIT, nm 3.0SCAN RATE. nm 2.0
FILTER slow
.416.30 - 1.479E+00
0.000
<200 300 400 500
Mi wavelength scan ---Tics every 100/20 nm
550>88
peptides fragments as observed for the control. Some of the unassigned peptides
correspond to auto-digestion of the enzyme as deduced form a blank digest (data not
shown). One peak at m/z 1639 could be assigned to the peptide V7 with an adduct
derived from the episulfonium ion of CEG (Figure 4.9). However, no other peptides
could be interpreted as originating from hemoglobin with the addition of one or more
alkylating moieties derived from CEG.
Discussion
The results of this study demonstrate that the episulfonium ion of CEG is a
chemically reactive species towards hemoglobin at physiologic pH, but that very high
amounts of CEG are necessary before alkylation is observed. Attempts to alkylate
hemoglobin with molar excesses of CEG on the order of 10- to 20-fold did not result
in any apparent adduct formation.It was not until CEG was in the range of 100-fold
excess that alkylation could be detected by MALDI mass spectrometry. In
comparison, E. coli thioredoxin showed evidence for adducts with a 5-fold molar
excess of CEG to thioredoxin (Erve, et al., 1995a). This implies that at least 20 times
more CEG is required to show signs of allcylation on hemoglobin as compared with
thioredoxin. When adducts were observed, they were found on both chains of
hemoglobin. This observation implies that CEG is capable of reacting with a
nucleophilic amino acid on hemoglobin other than cysteine since there are no accesible
cysteines on the a-chain. The spectrophotometric experiment was to specifically
determine whether Cys-93 on the 0-chain of hemoglobin was a target of allcylation by
the episulfonium ion of CEG. Reaction with IAA, which combines readily with
sulfhydryl groups in the thiolate form, produced the expected results: a decrease in
the number of free sulfhydryl groups per mole of hemoglobin with increasing amounts
of IAA. This observation confirmed both the validity of the assay and that the
sulfhydryl groups were indeed free and available to react. Performing an identicalL
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alkylation experiment with CEG instead of IAA did not show an analogous decrease
in the number of free sulfhydryl groups per mole of hemoglobin with increasing
amounts of CEG. These results strongly suggest that the Cys-93 on the 13-chain of
hemoglobin is not a target for allcylation by the episulfonium ion of CEG. A possible
explanation for this lack of reactivity might be that a combination of electrostatic and
steric factors prevent the positively charged episulfonium ion from accessing this
cysteine. The lack of reactivity of iodoacetic acid towards Cys-93 on the 13-chain of
hemoglobin is thought to be due to charge interactions with certain amino acid side
chains that prevents access to Cys-93 (Garel, et al., 1982 ).Moreover, the 13-93
cysteine sits in the heme pocket which has substantial hydrophobic character. This
allows a number of aromatic alkylating species such as 4-aminobiphenyl to react at
this cysteine (Ringe, et al., 1988), but may result in the exclusion of a charged
hydrophilic species such as the episulfonium ion of CEG. The absorption spectra for
CEG treated hemoglobin showed changes not seen in the control. In particular, a shift
in the Soret band was seen for two of the three treated samples from 416 nm to 413
nm and 411 nm for the 250- and 500-fold excess CEG treated samples, respectively.
The Soret band is an intense peak that represents absorption of the heme group. In
oxyhemoglobin it is at 415 nm, whereas oxidation to methemoglobin shifts this to 406
nm (van Kampen and Zijistra, 1983). It is thus possible that a trace metal impurity
present in CEG caused oxidation, by Fenton chemistry, of ferrous iron to ferric iron
with the resulting shift in wavelength. An alternative possibility is that CEG was
bound near the heme pocket and caused a perturbation of the conjugated heme. In
addition, a flattening of the aromatic absorption region at 280 nm for the highest level
CEG treated sample was observed. These changes could reflect modification of
tyrosine by the episulfonium ion of CEG. Strong evidence exists for alkylation by the
episulfonium ion of CEG of tyrosine in oxytocin (Erve, Deinzer and Reed, 1995b) and
E. coli thioredoxin (Erve, et al., 1995a). There are a total of 38 histidine residues in
hemoglobin, some of which are on the surface of the protein and, therefore, exposed to
solvent (Dickerson and Geis, 1983). Two of these histidines, 3 -His -143 and a-His-20,
were shown to be alkylated by styrene oxide (Kaur, et al., 1989). There is also91
evidence that the imidazole ring of histidine may undergo alkylation by the
episulfonium ion of CEG (Jean and Reed, 1989). Therefore, it seems reasonable to
propose that at least some of the adducts observed in these experiments are due to
alkylation at histidine. Interestingly, the single peptide in the FAB mass spectrum of
the CEG-treated hemoglobin digest that might be alkylated by the episulfonium ion of
CEG was V7. This peptide contains the 13-93 cysteine and two histidines at position
92 and 97, all of which are theoretical targets. However, the histidines correspond to
the proximal and distal histidines and are involved in heme and oxygen binding,
respectively (Dickerson and Geis, 1983). Consequently, they would not seem likely
targets for alkylation. In light of the fact that Cys-93 did not show evidence for
reaction, it remains questionable whether this peptide at m/z 1639 is indeed alkylated
by the episulfonium ion of CEG.In mouse hemoglobin treated with radiolabelled
DCE, cysteine was found to be alkylated by CEG three times greater than histidine, as
determined by ion-exchange chromatography (Svensson and Osterman -Golkar, 1986).
These workers also determined that the microsomal metabolic product, 2-
chloroacetaldehyde, bound to cysteine about 20 times greater than CEG. It should be
noted, however, that it is quite possible that the mouse hemoglobin tertiary structure
may differ significantly from human hemoglobin which could explain the observed
differences in work reported here with the findings of Svensson (Svensson and
Osterman-Golkar, 1986).
Further work is needed in order to make any definitive statements regarding the
actual alkylation sites of the episulfonium ion of CEG on hemoglobin. The strategy
might consist of further enzymatic digestion and attempts to identifying alkylated
peptides by MALDI mass spectrometry, which seems to have better sensitivity towards
CEG-alkylated peptides than FAB mass spectrometry as suggested by work with
thioredoxin (Erve, et al., 1995a). Specific enzymatic digestion coupled with mass
spectrometry has been used to identify single amino acid substitutions present in an
abnormal hemoglobin (Jensen, et al., 1991). However, in these applications the
experiments were conducted on a pure a or 13 chain variant. A problem that remains
to be solved here is the adequate separation of an individual adduct from unreacted92
hemoglobin or other adducts. Until this is accomplished, it will be difficult to obtain
conclusive evidence for alkylation at a specific amino acid. As adducts are only
formed at very high levels of CEG over hemoglobin, there seems little chance that
hemoglobin adducts could serve as biomarkers of exposure to DCE in the work
environment.Nevertheless, this work illustrates the importance of considering the
protein tertiary structure surrounding a functional group, in addition to it's
nucleophilicity, when deciding whether an alkylating agent will alkylate a particular
amino acid.93
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Chapter VI
Conclusion
Summary
Based on the work of Paul Jean, it was shown that certain functional groups of
dipeptides are extensively alkylated to a larger degree than DNA (Jean, 1991).The
investigations described in my thesis have extended his work to show that CEG can
indeed react with peptides and proteins and that the sulfhydryl group is the major
target when it is available, as is the case for reduced oxytocin and Cys-32 of E. coil
thioredoxin.It is possible, however, that protein sulfhydryl groups will not react,
ostensibly due to steric hindrance as was observed for Cys-35 of E coli thioredoxin.
Electrostatic repulsion between the positively charged episulfonium ion of CEG and
positively charged residues on hemoglobin may explain the lack of reactivity of (3-93
Cys for human hemoglobin. Thus, CEG is selective for protein thiols over other
functional groups in proteins and is even selective amongst proteins containing thiols.
Tandem mass spectrometry was demonstrated capable of identifying some alkylation
sites in oxytocin and E. coli thioredoxin. Extensive fragmentation of the alkylating
moiety was noted, specifically, the loss of a glycyl or a glutamyl residue. Fortunately,
the sulfur adduct bond was not broken during CD allowing cysteine to be
unequivocally identified as an alkylation site. In contrast, other nucleophilic sites in
peptides and proteins, such as, tyrosine and N-terminal amino groups appear to be
more labile. A possible explanation is that amechanism exists by which these bonds
can be more easily broken than the sulfuradduct bond; this possibility has not been
further explored.
The significance of the finding that proteins can be alkylated by CEG in vitro
at physiologic pH indicates that protein alkylation by CEG may be an importantfacet95
of the hepatotoxic and nephrotoxic effects observed for DCE in vivo. Modification
and loss of critical thiols is one possibility that has been used to explain the
mechanism of action of some chemicals (Snyder, 1990). Regarding CEG, the finding
that an active site cysteine in the important redox enzyme thioredoxin is the major
amino acid target in vitro, at molar levels of CEG only slightly higher than that of the
enzyme, suggest that irreversible alkylation could inactivate a critical cytosolic
enzyme. It remains to be seen whether a major portion of toxicity of DCE in vivo is
associated with the loss of this specific protein function due to this alkylation event.
It is known, however, that the capability of thioredoxin to reduce the disulfide bonds
in insulin is lost following CEG alkylation in vitro (Meyer, et al., 1994).
Nevertheless, understanding the toxicologic significance of protein covalent binding
requires not only identification of the target protein, but also the amino acid residue
that has been modified as well. My thesis work has demonstrated, with E coli
thioredoxin, the feasibility of using mass spectrometry to identify alkylation sites that
may be applied to other proteins as well.
Future Work
Based on the results of E. coli thioredoxin alkylation, and what is known about
this multi-faceted enzyme, I would recommend that future research investigate whether
thioredoxin is selectively alkylated in vivo following treatment with a toxic dose of
DCE or BCE. A strategy used to accomplish this could entail the use of an antibody
directed towards mammalian thioredoxin which would allow its isolation from a
mixture of cytosolic hepatic proteins. Following isolation, MALDI mass spectrometry
could confirm whether or not it was alkylated by CEG. Immunologic approaches for
adduct detection and quantitation by enzyme-linked immunosorbent assay were first
applied to DNA adducts (Leng, 1985; Strickland and Boyle, 1984). Today,
immunologic approaches are frequently applied towards detection of protein adducts as
well (Poirier, 1993). For example, antibodies have been produced and used to detect96
acetaldehyde adducts present on hemoglobin resulting from ethanol metabolism as a
means of monitoring alcohol consumption (Lin, et al., 1993; Niemela, et al., 1990) and
to detect adducts arising from benzene exposure (Grassman and Haas, 1993). A
difficulty encountered isolating a particular protein adduct, however, is that the adduct
might not be easily accessible to the antibody due to steric reasons, resulting in a
decrease in sensitivity. To overcome this problem, Day and coworkers have
developed a procedure that first enzymatically digests the protein to expose the adduct
before application of immmoaffinity chromatography to isolate the adduct of interest
(Day, et al., 1990). Therefore, an alternative strategy could involve digestion of
cytosolic proteins with trypsin to generate a mixture of peptides. The peptides would
then be applied to an immunoaffinity column that recognizes CEG adducted cysteine
which would hopefully allow isolation of a CEG adducted tryptic peptide. If the
peptide were derived from thioredoxin, it would be identified from the sequence of the
peptide. Other protein targets might be identified as well by attempting to match the
tryptic peptide sequence with a protein data base. In order for this approach to
succeed it will be necessary to generate an antibody that recognizes the adduct derived
from the episulfonium ion of CEG on protein.
In light of the fact that chloracetaldehyde has been postulated to be involved in
the toxicity of DCE, it would be of interest to use E. coli thioredoxin as a model to
compare the alkylating ability of CEG to chloracetaldehyde. Questions that could be
answered include:1) does chloracetaldehyde alkylate thioredoxin?; if it does, 2) how
do the alkylation levels compare to those of CEG, and, 3) does chloracetaldehyde
alkylate the active site cysteines? With the techniques already developed to study
thioredoxin/CEG alkylation, it would be a simple matter to perform the necessary
experiments to answer these questions. Information gathered would help to clarify the
possible contribution to protein alkylation from the P450 pathway as compared to the
GSH pathway.97
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APPENDIX A
CEG alkylation Assay
Introduction:
The purpose of this assay is to determine the reactivity of purified CEG towards thiols
by measuring the disappearance of the glutathione thiol as a function of added CEG.
Materials & Method:
Purified CEG, approximately 3 mg.
10 mM GSH in 0.2M NH,HCO, pH 7.4.I also add 1 mM Bathophenanthroline-
disulfonic acid (BPDS) (sodium salt) to help stabilize the GSH towards oxidation.
1 mM 4,4'-pyridine disulfide (PDS)
Make up a 10 mM GSH solution by adding 30.7 mg GSH and 4.9 mg BPDS to 10
milliliters of buffer.
Assay:
Part A: CEG alkylation of GSH
Use at least 3 levels of CEG (Table Al). The molar ratios of CEG to GSH were:
0.5, 1.0 and 5.0. Weigh out the CEG into an Eppendorf tube and then add 100
!IL of the GSH solution. Let react for 90 minutes to ensure that the full alkylating
capacity of the CEG is utilized. Also take some CEG and hydrolyze it before adding
the GSH. This is a negative control.116
Table Al.
Sample
Samples used in the CEG assay.
Excess GSH (A)CEG (11G)
A 1/2 200 370
B 1 100 370
C 5 100 1850
D 100 370*
GSH 0 100
* Hydrolyzed to HEG.
Part B: Spectrometric Determination of GSH
Take 20 p.L of each reaction mixture and add it to 10 pL of 0.05M phosphate buffer,
pH 7.4 in a volumetric flask. Pour solution into a ten mL beaker and then aliquot 2.9
mL into 3 glass vials. Then add 50 111_, PDS solution and let incubate for 10 minutes.
Record absorbance at 324 nm. A PDS blank is also prepared and its absorbance
subtracted. Calculate [SH] using E32420,117 cm-IM-1.
Plot [SH] versus CEG/GSH ratio.117
APPENDIX B
Derivitization of Wang Resin with Fmoc-glycine
Introduction:
This method will describe the procedure for derivatizing the Wang resin, the first step
in the procedure for synthesizing labeled glutathione. Reference: Grandas et al.
Anchoring of Fmoc-amino acids to hydroxymethyl resins (1989) International Journal
of Protein and Peptide Research 33, pp 386-390.
Materials:
from Bachem, Torrance, CA.-
Fmoc glycine 297.3 g/mole or Fmoc 'N-glycine from Isotec,
4-alkoxybenzyl alcohol polystyrene 'Wang Resin' 0.95 mequiv/g
diisopropylcarbodiimide (DCI) 126.2 g/moledensity= 0.81 g/mL
N-methymorpholine (NMM) 101.1 g/moledensity= 0.92 g/mL
1-hydroxybenzotriazole (HOBt) 135.1 g/mole
Solvents: dimethylacetamide (DMA), dichloromethane (DCM), methanol
1-acetylamidazole, from Aldrich.
3:3:2.25:0.3:1 (aa:DIC:H013t:NMM:Resin)
Method:
Step One: Weigh out 508 mg Fmoc glycine and dissolve in 3 mL of DMA. Weigh
out 173.0 mg HOBt and dissolve in 0.6 mL DMA and then mix with the Fmocglycine
with stirring and chill on an ice bath. Add 0.266 mL DIC in 0.4 mL DMA, also
chilled, to the above mixture and stir for 5 to 10 minutes. To 0.6 g (0.57 mequiv) of
Wang resin in a ten milliliter conical flask, add the prepared mixture and place in a
sonicator and let react at room temp. for17 hours. (temp will actually be about
45°C)After about five hours, test the level of substitution.
Step Two: To wash the resin prior to performing the spectrophotometric assay,
withdraw0.5 mL of the resin mixture with a glass pipette and place on a filter flask118
connected to a vacuum. Wash with 15 mL DMA, 15 mL DCM, 15 mL Me0H
followed by another 15 mL of DCM. If the resin is clumped, it can be ground gently
with a glass stir rod. After completely washing the resin, it should appear white and
the faint yellow color seen initially should have disappeared. Next, cover with a
Kimwipe (using a rubber-band to fasten to the funnel) and place in a vacuum
desccicator for a minimum of 30 minutes. When measuring the final resin, maintain
under vacuum for 3 hours or until it has a constant dry weight.
Step Three: To perform the spectrophotometric assay to measure the substitution
level, weigh into a 5 mL glass test tube approximately 5-6 mg of the dry resin. Then
dissolve it in 0.4 mL of DCM and add 0.4 mL of piperidine. Seal the test tube with
parafilm and let react for 30 minutes. Stop the reaction by adding 1.6 mL of
methanol. Filter out the resin by passing mixture through a small piece of glass wool
placed in the end of a glass pipette. Take 1 mL of the filtrate and dilute
volumetrically to 25 mL with DCM. Measure absorbance at X=301 nm.
Calculate: substitution level (mmole/g) = A301E x (25 mL / mg resin)
E = 7800 M-1 cm' for fulvene-piperidine adduct.
Step Four: Wash the resin by placing it on the frit in the reaction vessel. The
reaction vessel is connected to an aspirator and a nitrogen tank. Adjust the nitrogen so
that the flow causes semi-vigorous mixing. Wash the resin with 1) 10X 10 mL DMA,
2) 10X 10 mL wash A (1:1 DMA/DCM) 3) 5X 10 mL DMA.
Step Five: Prepare a 0.3M solution of 1-acetylamidazole in DMA. (0.51g in 15 mL).
Add ten milliliters to the reaction vessel, adjust the nitrogen to give gentle mixing, and
attach a drying tube to the top of the reaction vessel. Let the acetlyation reaction
proceed 30 minutes so that any free hydroxyl groups are end-capped. After the
reaction is completed, wash the acetylated resin again: 1)10X 10 mL DMA, 2)10X 10
mL Wash A, 3) 5X 10 mL DCM, 4) 5X 10 mL Me0H. Transfer the resin to a119
pre-weighed vial, rubberband a kimwipe over the mouth of the vial and place in the
vacuum desiccator overnight. The next day, re measure the substitution level of the
end-capped resin prior to using it for peptide synthesis.
Glutathione Synthesis using the Wang Resin
Introduction:
This method will describe the procedure for manual synthesis of 15N labeled
glutathione using the Wang resin derivatized with Fmoc 15N-glycine.
Materials:
from Bachern, Torrance, CA-
N-Fmoc glutamic acid a-t-butyl ester 585.7 g/mole
N-Fmoc trityl-cysteine 425.5 g/mole
N-Fmoc IN-glycine derivatized Wang resin
Method:
Part A-Coupling-
Add the derivatized dry resin to the reaction vessel using some DMAas necessary.
The reaction vessel should be connected to the vacuum and have the nitrogengas
adjusted to provide gentle mixing during the steps that follow. Perform the following
steps in order: (1) Wash the resin with 10 X 10 mL wash A Let resin swell in DMA.
(2) Add 5 mL of piperidine/toluene/DMA (30:35:35 v/v/v). Mix for three minutes
and filter. Repeat but allow 10 minutes of mixing.This step removes the Fmoc
group ie. is a deprotection step (3) Wash resin again with 10 X 10 mL wash A (4)
Add the amino acid to be coupled with HOBt and DIC in DCM. Prepare as follows:
Mix 4 eq. amino acid + 4 eq. HOBt in enough DMA to give a 0.4 M solution of the
amino acid. (the volume of DMA should be1.5 to 2.5 mL) Separately, prepare a 0.4
M solution of DIC in DCM, using the same volume as that used to dissolve the amino
acid. (623 mL DIC in ten mL DCM) Mix these two solutions and allow to stand for
two minutes before adding to the resin. (5) Let the coupling reaction proceed for two120
hours and filter. (6) Wash resin with 10 X 10m1 wash A. (7) Usinga spatula,
remove some of the resin by dipping it into the reaction vessel and transferring it toa
5 mL glass test-tube. Add the 5 drops each of the three reagents comprisingthe
Ninhydrin solution. Incubate for five minutes at 100°C. A yellow colorindicates a
successful coupling. Proceed with next coupling by repeatingsteps (1) through (5). A
dark blue color means that the coupling has not occurred. Filter the resinand go
back to step (4). A light blue colormeans that the reaction is not quite complete. Let
reaction go for another hour. (9) When the last coupling is finished afterstep (7)
repeat steps (2) and (3).(10) Wash resin with 5 X 10 mL /CM. (11) Wash resin
5 X 5 mL Me0H. (12) Transfer resin to a pre-weighed g's vial and dry in a vacuum
desiccator overnight.
Resin Cleavage and Work-up
Introduction:
This method will describe how the peptide GSH is cleaved from the resin and
recovered.
Materials:
Mix the following chemicals to make reagent K-
TFA 4.125 mL
H2O 0.25 mL
ethanedithiol 0.125 mL (Warning -Stench Hazard!!)
thioanisole 0.25 mL
phenol 0.25 g
Method:
Step one: Place the resin in a 10 mL round bottom glass vial. Prepare
reagent K as a cocktail. Mix the smaller volumes first before combining with TFA.
Add to the resin with stirring using a magnetic stir bar. Toa 12 gauge needle, attach
a balloon and put it through the septum. Fill the vessel with N2 gas until the balloon121
fills before evacuating the vessel by opening the vacuum. Close the vacuum and refill
with N2 gas. Repeat once again. Make sure that the balloon is filled with gas as the
cleavage reaction proceeds over the next 2 hours.
Step Two: Filter resin using a small filter funnel. To the vessel into which the filtrate
will go, add an attachment that will allow the vacuum to be used to aid in getting
every drop off the filtrate (it contains the precious peptide!) Washthe filtrate with2
mL of TFA. Rinse the reaction vessel with TFA and pass the wash through the filter
to combine with the filtrate.
Step Three:Prepare40 mL of 10% acetic acid in water. Add 10 mL to the filtrate
which will immediately tum the filtrate milky white. Transfer to a separator)/ funnel.
Use the rest of the acetic acid to wash the vessel and transfer to the sep funnel.
Step Four: Extract with 50 mL of anhydrous ether. Shake gently to avoid forming an
emulsion. Drain the bottom aqueous layer into another separatory funnel and repeat
the ether extraction twice, draining the aqueous layer into the other sep funnel. After
the third extraction, put the aqueous layer into a lyophili7ation jar. Freeze sample and
lyophilize overnight.